Systems and methods for treating cardiac dysfunction

Information

  • Patent Grant
  • 12310853
  • Patent Number
    12,310,853
  • Date Filed
    Friday, May 19, 2023
    2 years ago
  • Date Issued
    Tuesday, May 27, 2025
    a month ago
Abstract
A system for treating cardiac dysfunction can include an expandable device for insertion into a heart, a foot configured to contact a portion of the heart, a support frame, and a membrane coupled to the support frame. The support frame can include a plurality of radially expandable struts each having a first free end configured to extend beyond the foot and a second end coupled to the foot. The plurality of radially expandable struts can include a plurality of staggered stops, and each of the stops can be positioned on a respective one of the struts proximal to the first free end of the respective one of the struts. Method for treating cardiac dysfunction can include implanting the systems described herein into a chamber of the heart.
Description
TECHNICAL FIELD

Described herein are ventricular devices useful for treating cardiac dysfunction.


BACKGROUND

Congestive heart failure (CHF) is a chronic medical condition in which the heart progressively enlarges. The enlarged heart cannot deliver sufficient oxygenated and nutrient rich blood to the body's cells. CHF is commonly associated with left ventricular dysfunction and/or diastolic dysfunction. Left ventricular dysfunction results from impaired emptying of the left ventricular heart chamber. In contrast, diastolic dysfunction refers to alterations in left ventricular properties that adversely affect ventricular filling and diastolic pressure.


A key aspect of normal diastolic filling is the contribution of left ventricular elastic recoil forces to left ventricular filling. Elastic recoil is the ability of the stretched heart to return to its resting position. For example, in a healthy heart, the end-diastolic dimension of the left ventricle may range from 36-56 mm (relaxed) and the end-systolic dimension of the left ventricle may range from 20-40 mm (contracted). A left ventricle in heart failure would typically have larger dimensions than those of a healthy heart. Elastic recoil forces are important in early diastole because they allow rapid and enhanced early filling by assisting the expansion of the left ventricle.


In the case of heart enlargement and/or a decrease in myocardial function, elastic recoil forces may be reduced or absent, thus ceasing to assist early ventricular filling and leading to an increase of the ventricular filling pressure. For example, a patient experiencing CHF typically has an ejection fraction of 40% or less.


Thus, there is a need for a new and useful system, device, and method for treating cardiac dysfunction. This new and useful apparatuses (e.g., systems, devices, and assemblies) and methods described herein may address these needs.


SUMMARY

Described herein are devices and systems for treating a cardiac dysfunction. In general, the devices and systems described herein may include improved expandable implant devices that can be collapsed for insertion into a ventricle of a human heart, and then expanded when in the heart. In general, the implants described herein are improved over earlier generations of implants because they may be used more safely and reliably. In particular, such devices may include a support frame having a plurality of expandable struts, to which a membrane is attached, where the struts are configured for cyclical loading. The struts of the support frame may have a roughness average of less than 1 μm. These expandable implants may also include a foot configured for contacting a first interior wall portion of the ventricle, wherein the first free ends of the struts extend beyond a diameter of the foot. The foot may have a durometer of between about 70 A to 90 A.


For example, an expandable device for inserting into a ventricle of a heart to treat heart failure may be characterized in that the device has: a support frame comprising a plurality of radially expandable struts, wherein each strut has a first free end and a second end, and wherein the struts are configured for cyclical loading; a foot configured for contacting a first interior wall portion of the ventricle, wherein the first free ends of the struts extend beyond a diameter of the foot; and a membrane coupled to the support frame.


Each of the first ends of the plurality of struts may comprise an anchor for engaging a second interior wall portion of a heart. The anchors may be staggered. Each strut may include a stop proximate the anchor, the stop may be adapted to keep the membrane in place on the support frame while also being adapted to reduce or prevent over-penetration of the strut into the second interior wall portion of the heart. The stop may include an eyelet.


The struts are adapted for cyclic loading. Cyclic loading means that the struts are configured to move (e.g. flex or bend) as the heart, and particularly the ventricle, beats. In addition, the membrane attached to the struts may push against blood flowing in the ventricle, and assist in ejecting blood from the ventricle. Repeated cyclic loading may weaken struts over time, which is particularly critical when the device is implanted into a heart. Thus, the struts described herein may be shaped with a curve and/or varying thickness, particularly in regions prone to stress fractures. For example, the struts may have a thickness that varies along the length of the struts. This is illustrated in greater detail below.


The support frame generally has a collapsed delivery configuration and an expanded deployed configuration.


The second ends of the plurality of struts may be flared, such that the width of the second ends is greater than the width of the first ends. A slot region may be disposed between two struts (e.g., between adjacent struts).


The support frame may have a roughness average of less than 1 μm.


In general, the foot may comprise a radiopaque material. The foot may be compressible or bendable. The foot may have a durometer between about 70 A to 90 A. The foot may have a height between about 0.5 mm to 4.0 mm.


For example, an expandable device for inserting into a ventricle of a heart to treat heart failure may be characterized in that the device has: a foot configured for contacting a first interior wall portion of a heart, wherein the foot has a durometer between about 70 A to 90 A; a support frame comprising a plurality of radially expandable struts configured for cyclical loading, wherein each strut has a first free end and a second end configured to extend beyond the foot; and a membrane coupled to the support frame, wherein each strut includes a stop proximate the free end, the stop adapted to keep the membrane in place on the support frame while also being adapted to reduce or prevent over-penetration of the strut into the second interior wall portion of the heart.


Also described herein are systems including both an expandable device, including any of the improved expandable devices described above, and a delivery catheter.


For example, a system including an expandable device for inserting into a heart ventricle to treat heart failure and a delivery catheter for deploying the expandable device into the ventricle may be characterized (improved from other such systems) in that the system includes: the expandable device comprising: a foot for contacting a first interior wall portion of a heart; a support frame comprising a plurality of radially expandable struts, wherein each strut has a first free end and a second end coupled to the foot; and a membrane coupled to the support frame; and the delivery catheter having: a proximal end and a distal end; an expansion member near the distal end of the delivery catheter configured to apply pressure to the support frame of the ventricular partitioning device to move the ventricular partitioning device from a collapsed delivery configuration to an expanded deployed configuration; and a coupling element configured to secure the expansion member to the ventricular partitioning device during deployment.


In general the expandable device (which may also be referred to as a ventricular partitioning device herein) may be configured to be loaded into a guide catheter using a funnel coupleable to a sleeve, as described in greater detail below. The system first ends of the plurality of struts may comprise an anchor for engaging a second interior wall portion of a heart. The anchors on the first ends of the plurality of struts may be configured to penetrate the second interior wall portion of the heart upon expanding the ventricular partitioning device. The coupling element may comprise a helical screw.


As mentioned above, the support frame may have a roughness average of less than 1 μm, and the foot may have a durometer between about 70 A to 90 A.


Any of these systems may also include a funnel with a flared first end and a second end, wherein the flared first end is configured for receiving the expandable device. Any of the funnels may include a sleeve removably coupled to the second end of the funnel, wherein the sleeve is configured to transfer the expandable device to a guide catheter.


For example, a system may include including an expandable device for inserting into a heart ventricle to treat heart failure and a delivery catheter for deploying the expandable device into the ventricle, characterized in that the system comprises: the expandable device having: a foot for contacting a first interior wall portion of a heart having a durometer between about 70 A to 90 A; a support frame having a roughness average of less than 1 μm, the support frame comprising a plurality of radially expandable struts, wherein each strut has a first free end and a second end coupled to the foot; and a membrane coupled to the support frame; the delivery catheter having: a proximal end and a distal end; an expansion member near the distal end of the delivery catheter configured to apply pressure to the support frame of the expandable device to move the expandable device from a collapsed delivery configuration to an expanded deployed configuration; and a coupling element configured to secure the expansion member to the expandable device during deployment.


Also described herein are systems or devices for loading the implant (expandable devices) described above. These device or systems may include a funnel and a releasably coupled sleeve. An implant may be coupled with the funnel and sleeve, for transferring to a delivery catheter.


For example, described herein are implant loading systems including a funnel for loading an expandable implant into a guide catheter for delivery to a ventricle to treat heart failure, characterized in that the implant loading system comprises: the funnel having: a flared first end and a second end, wherein the flared first end is configured for receiving and collapsing expandable implant; and a sleeve removably coupled to the second end of the funnel, wherein the sleeve is configured to transfer the expandable implant to a guide catheter.


The funnel may include a first portion at the first end and a second portion at the second end, the first portion comprising a tapering receptacle for receiving the expandable implant, and the second portion comprising a lumen having a first diameter.


The sleeve may include a lumen with a second diameter, wherein the first diameter is greater than the second diameter. The sleeve may also include a coupling element located in a center portion of the sleeve.


The sleeve may comprise a tubular portion distal to the coupling element, the tubular portion may be configured to be inserted into the second portion of the funnel. The tubular portion of the sleeve may have a length that is about equal to the length of the lumen of the second portion of the funnel.


In general, any of the implants described herein may be used with the implant loading devices and systems. For example, an expandable implant that may be used (or included with) these systems and devices may comprise: a foot; a support frame comprising a plurality of radially expandable struts, wherein each strut has a first free end and a second end coupled to the foot; and a membrane coupled to the support frame.


The flared first end of the funnel may be configured for receiving the first free end of the plurality of radially expandable struts. The implant loading system may be coupled to the expandable implant.


For example, an implant loading system including a funnel for loading an expandable implant into a guide catheter for delivery to a ventricle to treat heart failure, characterized in that the implant loading system comprises: the funnel having: a flared first end and a second end, wherein the flared first end comprises a tapering receptacle for receiving and collapsing the expandable implant, and a second portion at the second end comprising a lumen having a first diameter; and a sleeve removably coupled to the second end of the funnel, wherein the sleeve is configured to transfer the expandable implant to a guide catheter; a coupling element located in a center portion of the sleeve; and a tubular portion distal to the coupling element, the tubular portion configured to be inserted into the second portion of the funnel.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a ventricular partitioning device in accordance with a preferred embodiment;



FIGS. 2A-2D illustrate a foot of a ventricular partitioning device in accordance with a preferred embodiment;



FIGS. 3A-3C illustrate a foot of a ventricular partitioning device in accordance with an alternative preferred embodiment;



FIGS. 4A-4C illustrate a stem for coupling a membrane to a foot of a ventricular partitioning device, in accordance with a preferred embodiment;



FIGS. 5A and 5B illustrate a top and side view of a membrane coupled to a support frame of a ventricular partitioning device, respectively, in accordance with a preferred embodiment;



FIGS. 6A-6C illustrate two embodiments of the struts of a ventricular partitioning device;



FIGS. 7A-7D illustrate a support frame, in accordance with a preferred embodiment;



FIGS. 8A-8D illustrate an exterior view of an implant loading system for a ventricular partitioning device, in accordance with a preferred embodiment;



FIGS. 9A-9C illustrate a cross-sectional view of an implant loading system for a ventricular partitioning device, in accordance with a preferred embodiment;



FIGS. 10A-10D illustrates an implant loading system for a ventricular partitioning device, in accordance with an alternative preferred embodiment;



FIG. 11 illustrates a delivery catheter for a ventricular partitioning device, in accordance with a preferred embodiment; and



FIG. 12 describes a method of using a delivery system for a ventricular partitioning device, in accordance with a preferred embodiment.





DETAILED DESCRIPTION

Disclosed herein are systems and devices for treating cardiac dysfunction. In some instances, cardiac dysfunction may include diastolic dysfunction, mitral valve regurgitation, and/or heart failure.


In general, the systems and devices described herein may be used to treat a patient's heart suffering from heart failure. The systems and devices may be used to treat a patient's heart experiencing diastolic dysfunction or a condition exhibiting characteristics of diastolic dysfunction, and may involve implanting within a ventricle of the heart a device that partitions the ventricle into functional and nonfunctional portions. In some embodiments, the device may deform during systole and recoil during diastole to supplement the natural elastic recoil action of the ventricle. In some embodiments, the device may reduce the end-diastolic volume, end-diastolic pressure, and/or increase the ejection fraction.


Diastole represents the period of time in the heart cycle in which the ventricles are relaxed and not contracting. Throughout most of diastole, blood is passively flowing from the right and left atria into the right and left ventricles, respectively. As the ventricles begin to contract, the pressure in the ventricles exceeds that of the atria, and the mitral valve closes, ending diastole. At this time, the ventricular pressure and volume are referred to as end-diastolic pressure and end-diastolic volume, respectively.


Reduced ventricular compliance, for example due to an increased stiffness in the ventricular heart wall, may result in increased end-diastolic pressure and decreased end-diastolic volume. Diastolic dysfunction may also result from changes in left ventricle relaxation during diastole. For example, inotropic stimulation, fast heart rates, non-uniform heart activation, and altered timing of forces that oppose ventricular ejection may contribute to altered left ventricle relaxation.


Devices



FIG. 1 illustrates an expandable device, which may also be referred to as a ventricular partitioning device, 1 to treat cardiac dysfunction. In some embodiments, cardiac dysfunction may include diastolic dysfunction, mitral valve regurgitation, heart failure, and/or any other type of malady of the heart. The device may be delivered to the ventricle of a patient to treat cardiac dysfunction. In some embodiments, as shown in FIG. 1, a device for treating cardiac dysfunction may include a foot 2 for contacting a first interior wall portion of a heart. Further, in some embodiments, a device for treating cardiac dysfunction may include a support frame 3 including a plurality of radially expandable struts 4 and a membrane 5 coupled to the support frame 3. Each of the radially expandable struts 4 has a first free end 4a and a second end 4b coupled to the foot 2.



FIGS. 2A-2D and 3A-3C illustrate a foot 2 coupled to a stem 6 of an expandable device in accordance with a preferred embodiment and an alternative preferred embodiment, respectively. The foot 2 of a ventricular partitioning device may contact an interior wall portion of a heart of a patient experiencing cardiac dysfunction. An interior wall portion of a heart may include an apex of a ventricle. In some embodiments, the foot 2 may contact the apex of the ventricle so that the entire device is underneath the papillary muscle located in the ventricle, such that the ventricular partitioning device does not interfere with the heart valve in the apex of the ventricle. In some embodiments, the foot 2 may contact the apex of the ventricle atraumatically such that the apex of the ventricle does not incur damage, trauma, and/or significant injury.


The foot 2 of the device, as shown in FIGS. 2A-3C, is supportive such that it does not collapse upon itself once implanted. However, the foot 2 may also be flexible, such that the device does not create focal pressure points (e.g., “hot spots”) in the ventricle. To balance these properties of the ventricular partitioning device, the foot 2 of the ventricular partitioning device may include a thermoplastic elastomer. In some embodiments, the foot 2 may include thermoplastic silicone polyether polyurethane (TPU), such as DSM.


In some embodiments, as shown in FIGS. 2A-3C, the foot 2 may include a different material and/or durometer than the stem. In some embodiments, the foot 2 may include, Pursil TSPU, or any other thermoplastic material, such that the durometer is 70 A to 90 A, preferably 78 A to 84 A, and the flexural modulus or bending modulus is 15 MPa to 45 MPa, preferably 20 MPa to 40 MPa. In some embodiments, the stem 6 may include, elasthane TPU, or any other thermoplastic material, such that the durometer is 45 D to 75 D, preferably 50 D to 70 D, and the flexural modulus or bending modulus is 100 MPa to 400 MPa, preferably 145 MPa to 390 MPa.


In some embodiments, the foot 2 of the ventricular partitioning device may include a radiopaque filler material to aid in visualization of the implant during and/or after implantation of the ventricular partitioning device in the heart of a patient. In some embodiments, the foot 2 may include 20% radiopaque filler. Alternatively, the foot 2 and stem 6 may include 40% radiopaque filler and any other percent of radiopaque filler suitable to the application. For example, the foot 2 and/or stem 6 may include between about 10 and 50% radiopaque filler, or at least about 10, 20, 30, or 40% radioapaque filler.


In some embodiments, as shown in FIGS. 2C and 3C, the foot 2 may have a height H ranging from 0.5 mm to 4.0 mm and a diameter D ranging from 13 mm to 17 mm, depending on the distance between the apex of the ventricle and the papillary muscle in the ventricle. In some embodiments, the foot 2 of the ventricular partitioning device may comprise a plurality of sections or petals 7. In some embodiments, a foot 2 may include 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 petals, preferably 5 petals, as shown in FIGS. 2A, 2B, 3A, and 3C. The petals 7 may include a looped configuration such that each petal includes an aperture 7a. Alternatively, the petals may comprise a solid configuration. Each petal 7 may be coupled to at least two other petals 7 of the foot 2 of the ventricular partitioning device. Alternatively, each petal 7 of the foot 2 may be separate and uncoupled from the other petals 7 of the foot 2. In some embodiments, the foot may alternatively include a screw for securing the ventricular partitioning device to the apex, a hub, or any other component suitable for positioning a ventricular partitioning device in a heart.


In some embodiments, as shown in FIGS. 2A, 2C, and 2D, the petals 7 of the foot 2 may be curved or include an angled portion 8, such that the point of attachment 9 of the petals 7 to the stem 6 is held at a distance from the apex of the ventricle while the perimeter 10 of the petals 7 is contacting the apex of the ventricle, as shown in FIGS. 2A and 2B. Alternatively, as shown in FIGS. 3A and 3C, the petals 7 may be coupled to the stem 6 at a right angle (90°) to the stem 6, such that the entire perimeter 10 and/or surface area of the petals 7 of the foot 2 may contact the apex of the ventricle.


In some embodiments, as shown in FIGS. 3A-3C, the foot 2 may be used in a ventricular partitioning device for treating acute myocardial infarction in order to prevent cardiac remodeling or damage (configured as an endocardial implant). In this embodiment, the device is configured to be positioned immediately adjacent to the heart wall, for example similar to a patch, across from the region of the infarct.



FIGS. 2A-3C illustrate a stem 6 coupled to a foot 2 of a ventricular partitioning device, such that the stem 6 is configured to receive a support frame of a ventricular partitioning device, as shown in FIG. 1. In some embodiments, the stem 6 may be substantially rigid for coupling to the support frame. However, the stem 6 may also be flexible for increasing the elastic recoil force of the ventricular partitioning device. The stem 6, as shown in FIGS. 4A-4C, may include a base 11 and a shaft 12 for receiving a support frame. In some embodiments, as shown in FIG. 4A, the base 11 may include a flange 11a to create a strong bond between the stem 6 and the foot 2 of the ventricular partitioning device. For example, the petals of the foot may be injection molded around the base of the stem and flange. Alternatively, in some embodiments, the stem 6 may be coupled to the foot 2 by another mechanism, for example by screwing, soldering, sintering, snapping, locking, fastening, or any other type of reversible or irreversible coupling mechanism.



FIGS. 4B-4C illustrate a cross-section of a stem 6 of a ventricular partitioning device in accordance with a preferred embodiment. The stem 6 may serve as an interface between the foot 2 and the support frame 3 of the ventricular partitioning device. As shown in FIG. 4C, the foot 2 may be secured to the support frame 3 by a cross pin 13 or any other type of fastener. For example, the hub or shaft at the base of the support frame may slide over the shaft 12 of the stem 6, such that a pin 13 may be inserted through the cross-section of the stem 6 to couple the support frame 3 to the stem 6. Alternatively, the support frame may be soldered, fastened, glued, or otherwise reversibly or irreversibly coupled to the stem. In some embodiments, the shaft 12 of the stem 6 may be configured to receive a delivery catheter, as described below in association with FIG. 10. For example, the shaft 12 may include helical grooves 14 such that a shaft of the delivery catheter may be screwed into the shaft of the stem 6, as shown in FIGS. 2D, 4B, and 4C.



FIGS. 5A and 5B illustrate a top view and side view, respectively, of a membrane 5 coupled to a support frame 3 of a ventricular partitioning device in accordance with a preferred embodiment. The membrane 5 coupled to the support frame 3 is a pressure-receiving surface of the ventricular partitioning device, such that the elastic recoil force of the ventricle is improved when the ventricular partitioning device is implanted. The membrane 5 may be stretched over the struts to give the frame a disk like shape. The membrane 5 may include expanded Polytetrafuoroethylene (ePTFE) having a thickness between 0.01 mm and 1 mm, preferably about 0.08 mm. Alternatively, in some embodiments, the membrane 5 may include mesh, or other appropriate permeable, semi-permiable, or impermeable membranes. In some embodiments, the membrane 5 may be formed of a suitable biocompatible polymeric material including Nylon, PET (polyethylene terephthalate) and polyesters such as Hytrel. In some embodiments, the membrane 5 may be porous to facilitate tissue ingrowth after deployment within a patient's heart.


As shown in FIG. 5B, the first free ends 4a of the support frame 3 coupled to the membrane 5 may deflect away from the centerline axis of the ventricular partitioning device when the ventricular partitioning device is deployed in a ventricle. The deflection may improve the anchoring of the ventricular partitioning device to an interior wall of a ventricle.


In some embodiments, as shown in FIGS. 5A, 6A, and 6B, the support frame 3 may include a plurality of radially expandable struts 4. The struts 4 may be configured to support a membrane 5 coupled to the struts. The struts 4 may improve the elastic recoil properties of the membrane 5 coupled to the struts 4. In some embodiments, the struts 4 may be configured for anchoring the ventricular partitioning device to an interior wall of the ventricle. In some embodiments, the support frame 3 may include 5 struts, 10 struts, 15 struts, or 20 struts, preferably 16 struts. In some embodiments, each strut 4 may be 1 to 8 cm in length, preferably 3 to 6 cm. In some embodiments, the support frame 3 may be smoothed to a particular surface roughness to reduce trauma to the patient during delivery and improve characteristics of the ventricular partitioning device, such as corrosion resistance and durability. The support frame 3 may be electropolished, chemically treated, and/or mechanically polished by a wheel, tumbling, abrasion, sand blasting, chemical etching, and/or any other method of polishing to achieve a particular surface roughness. In some embodiments, the roughness average (Ra) of the support frame may be between 0.01 μm and 1 μm, preferably between 0.85 μm and 0.15 μm.


In some embodiments, as shown in FIGS. 6A-6C, each strut 4 of the support frame 3 may include a first free 4a end and a second end 4b coupled to the foot. The first free end 4a of the support frame 3 may include an anchor or barb 15 for coupling the support frame 3 to an interior wall portion of a heart. This anchoring may allow the ventricular partitioning device to contract and relax with each systolic and diastolic phase, respectively, of the heart cycle. Further, the anchoring may partition the heart into functional and non-functional portions, such that the non-functional portion is proximal to the foot of the ventricular partitioning device.


In some embodiments, as shown in FIGS. 6A-6C, a stop 16 may be located at or near the base of the anchors 15 proximal to the first free end 4a of the struts 4. The stop 16 may be a bulge, projection, or otherwise widening of a portion of the strut 4 near the first free end 4a, which serves to lock the support frame 3 in place and/or reduce or prevent over-penetration of the struts 4 into the ventricle wall. The length of the struts 4 may alternate between a short length strut and a long length strut so that the anchors 15 and/or stops 16 are staggered, which allows the struts 4 to be collapsed into a more compact diameter for delivery.


In some embodiments, as shown in FIG. 6A, each first free end 4a of the strut 4 of the support frame 3 may further include an eyelet 16a. The eyelet 16a may serve as a stop 16, as described above, and/or as a mechanism to couple the membrane to the support frame. During manufacturing, polymer may be melted near the eyelet 16a of the support frame 3 to couple the membrane to the support frame, such that the melted polymer may flow from one side of the strut 4 through the eyelet 16 to the other side of the strut 4 to couple the membrane to the struts 4. As shown in an alternative embodiment in FIGS. 6B-6C, the stop 16, as described above, may be manufactured without an eyelet, such that the polymer melts around the stop 16 and secures the membrane to the support frame 3.


In some embodiments, as shown in FIGS. 7A-7D, the struts may include a material such as, for example, Nitinol, stainless steel, titanium alloys, NiTi alloy, other metal alloys, or plastic composites. In some embodiments, the struts 4 and/or support frame 3 may include a material, which allows for compression of the first free ends towards the central axis during delivery and self expansion upon deployment of the ventricular partitioning device in a patient's heart. In some embodiments, the struts 4 and/or support frame 3 may be cut, for example by a laser, from a tube including Nitinol, stainless steel or a similar material. During manufacturing, a plurality of longitudinal cuts may extend from one end of the metal tube to a position offset from the other end of the tube, leaving a hub 17 from which the struts 4 extend. The cuts may result in a plurality of slots 18 between the struts 4. In some embodiments, as shown in FIG. 7 A, the spacing between the slots 18 may define the strut width W while the thickness of the tube may define the strut thickness T. In some embodiments, the spacing of the slots 18 around the tube may result in struts 4 having a cross-sectional width that is slightly greater than its cross-sectional thickness. This may be accomplished by the slot 18 having a slightly greater spacing than the thickness of the tube. In some embodiments, slightly greater may mean about 1, 2, 3, 4, 5, 10, 15, 20, or 25 percent, or may mean between about 1 to 25 percent, or may mean between about 5 to 20 percent.


In some embodiments, as shown in FIG. 7B, the base 4c of the strut 4 is the second end of the strut that couples to the foot and extends from the hub 17. The base 4c of the strut 4 may be flared such that the width of the strut 4 increases as it approaches the hub 17. In some embodiments, the flared base 4c may spread bending strains over a larger amount of material, thereby decreasing peak strains during manufacturing, loading of the implant within a catheter, and cyclical use in the ventricle after implantation. In some embodiments, the width of the strut 4 at the hub 17 may be about 5 to 25 percent larger than the width of the strut 4 at a middle portion of the strut 4. In some embodiments, the length of the flared base 4c may be about equal to the width of the flared base 4c at the hub 17. Alternatively, the length of the flared base 4c may be greater than about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, or 200 percent of the width of the flared base 4c at the hub 17. Alternatively, the length of the flared base 4c may be less than about 95, 90, 85, 80, 75, 70, 65, 60, 55, or 50 percent of the width of the flared base 4c at the hub 17. The flared base may be formed by tapering the slot as it reaches the hub.


As illustrated in FIG. 7C, in some embodiments, the flared base can have a base bend radius 19 that is sized to (1) reduce or limit peak strains during shape setting to reduce or prevent damage and cracking of the metal frame; (2) reduce or limit peak strains when the implant is loaded into the catheter and reduce or prevent plastic deformation of the metal; and (3) reduce or minimize the height of the implant. In some embodiments, the diameter of the support frame 3 in its free shape 3a can be slightly oversized relative to its laminated shape 3b so that the membrane will stay tight after lamination. For example, the support frame 3 can be oversized by about 3, 4, 5, 6, or 7 mm, or be oversized between about 2 to 10 mm. The lamination mold is designed to conform to the natural shape of the support frame 3 when it is reduced to the lamination diameter 3b. This ensures that the support frame 3 is free to move as designed with little or no alternating strain concentrations.


As shown in FIG. 7D, after lamination, there is a strut curvature 20 near the anchor on the free ends 4a of the struts 4 that is designed to optimize the angle of engagement with the left ventricle wall which improves retention of the implant in the left ventricle. In some embodiments, the strut curvature 20 has a radius of about 0.5 to 1.5 inches. In some embodiments, the angle of engagement is about 30 to 60 degrees.


In some embodiments as described above, the strut cross-section dimensions having a width slightly greater than the thickness, in conjunction with the flared base, may bias the strut so that it deflects outwardly without any significant twist. This may improve the strength of the struts and reduce strain.


System


In some embodiments, a delivery system for a ventricular partitioning device may include an implant loading system for collapsing the ventricular partitioning device into a substantially linear delivery configuration for passage into a delivery catheter and into a heart and expanding the ventricular partitioning device into an umbrella-like shape once the device is delivered into a heart. In some embodiments, the ventricular partitioning device may be delivered transapically, percutaneously, endovascularly, or through any other appropriate means or procedure. In some embodiments, the ventricular partitioning device is coupled to a shaft in a lumen of the delivery catheter, for example by screwing the ventricular partitioning device to a shaft in a lumen of the delivery catheter, as shown in FIG. 11.


Described below are two different embodiments of an implant loading system for loading a ventricular partitioning device into a delivery catheter. The system described in FIGS. 8A-9C is the preferred embodiment of the implant loading system. The system as shown in FIGS. 8A-9C requires fewer steps and components as compared to the implant loading system described in FIGS. 10A-10D. However, as evident to one of skill in the art, both implant loading systems may be used to load a ventricular partitioning device into a lumen of a delivery catheter for delivery to a heart of a patient.


In some embodiments, as shown in FIGS. 8A-9C, an implant loading system for a ventricular partitioning device may include a funnel 21 with a flared first end 21a and a second end 21b, wherein the flared first end 21a is configured for receiving a collapsed ventricular partitioning device 1, as shown in FIGS. 8B and 8D, and a sleeve 22 removably coupled to the second end 21b of the funnel 21, such that the sleeve 22 is configured to transfer the ventricular partitioning device 1 to a guide catheter, as shown in FIGS. 8C and 8D.



FIGS. 8A-8D and 9A-9C illustrate an exterior and cross-sectional view, respectively, of an implant loading system for a ventricular partitioning device, in accordance with a preferred embodiment. As shown in FIGS. 8A-8D, a ventricular partitioning device 1 may be coupled to a delivery catheter, 23, as described below. The ventricular partitioning device 1 may be collapsed by drawing at least two sutures, strings, ties, or threads together, such that the diameter of the membrane and thus the ventricular partitioning device is reduced, and the ventricular partitioning device 1 is at least partially collapsed around the delivery catheter 23. In some embodiments, the at least two sutures may be coupled by a tab, such that both sutures may be tensioned and the ventricular partitioning device at least partially collapsed by manipulating the tab. In some embodiments, the ventricular partitioning device may be positioned in the flared first end 21a of the funnel 21 with the first free ends of the struts of the ventricular partitioning device entering the flared first end 21a of the funnel 21 followed by the foot 2 of the ventricular partitioning device, as shown in FIG. 8D. The funnel 21 may function to fully collapse the ventricular partitioning device for advancement into a lumen of a guide catheter. In some embodiments, as shown in FIG. 8A, the second end 21b of the funnel 21 is removably coupled to a second end 22b of a sleeve 22, for example by threading 24 the funnel 21 onto the second end 22b of the sleeve 22, as shown in FIGS. 8A and 8C. In some embodiments, as shown in FIGS. 9A and 9C, the threads 24 for coupling the funnel 21 to the sleeve 22, as shown in FIG. 9B, are evident using a cross-sectional view of the funnel 21 and sleeve 22. Alternatively, the funnel 21 may be coupled to the sleeve 22 by any suitable mechanism. In some embodiments, the ventricular partitioning device coupled to the delivery catheter 23 may be advanced through the funnel 21 into the sleeve 22 for loading of the ventricular partitioning device into a lumen of a guide catheter. The first end 22a of the sleeve 22 may include a stop or tapering of the sleeve, such that the ventricular partitioning device does not protrude from the first end 22a of the sleeve 22 or extend out of the first end 22a of the sleeve 22, as shown in FIGS. 8A-8C. In some embodiments, the interior of the funnel 21 and sleeve 22 may include a smooth surface, for example without flashes or burrs, such that the ventricular partitioning device is not torn or scratched during loading, unloading, and advancing.


Once, the ventricular partitioning device is advanced into the sleeve 22 from the funnel 21, the funnel 21 may be uncoupled from the sleeve 22. In some embodiments, the second end 22b of the sleeve 22 may be coupled to a guide catheter using a dilator, such that the dilator may be rotated to increase or decrease the size of the aperture in the dilator. The ventricular partitioning device may be advanced from the sleeve into the lumen of the guide catheter. In some embodiments, the delivery catheter 23 coupled to the ventricular partitioning device may be advanced through the guide catheter lumen into a heart of a patient to position the ventricular partitioning device in the heart of the patient. In some embodiments, the sleeve may be removed from the delivery catheter by any suitable mechanism after advancing the ventricular partitioning device into the lumen of the guide catheter. Alternatively, the delivery catheter may be lengthened such that the sleeve may remain on the delivery catheter while the ventricular partitioning device is being positioned in a heart of a patient.


Alternatively, in some embodiments as shown in FIGS. 10A-10D, an implant loading system for a ventricular partitioning device may further include a loader 24 comprising a lumen housing a two-piece introducer 25, referred to herein as a loader introducer pair. Instead of a two-step loading procedure, as shown in FIGS. 8A-9C, the loading procedure shown in FIGS. 10A-10D includes at least two more steps. In some embodiments, as show in FIG. 10A, the funnel 26 for loading the ventricular partitioning device into the sleeve 27 may be truncated as compared to the funnel 21 shown in FIG. 8B. Similar to FIGS. 8A and 8D, the tapered end 26b of the funnel 26 may be coupled to the second end 27b of the sleeve 27 and the ventricular partitioning device coupled to the delivery catheter may be advanced from the funnel 26 into the sleeve 27. In some embodiments, as shown in FIG. 10C, once the ventricular partitioning device is collapsed and advanced through the funnel 26 into the sleeve 27, the funnel 26 may be uncoupled from the second end 27b of the sleeve 27 and the second end 24b of the loader introducer pair 24/25 may be coupled to the second end 27b of the sleeve 27. The loader introducer pair 24/25 may be coupled to the sleeve 27 by a helical screw, latching, snapping, fastening, or any other type of coupling mechanism. The first end 24a of the loader introducer pair 24/25 may be coupled to a guide catheter, such that the lumen of the loader introducer pair is continuous with the lumen of the guide catheter. In some embodiments, as shown in FIG. 10C, the coupling mechanism may include a slot 28 on the loader 24 and a pin, knob, protrusion, or port on the guide catheter, such that the slot 28 receives the pin or port and secures the loader 24 to the guide catheter. Alternatively, the loader 24 may be coupled to the guide catheter by a helical screw, snapping, latching, or any other type of coupling mechanism.


As shown in FIG. 10C, the ventricular partitioning device may be advanced from the sleeve 27 into the loader introducer pair 24/25 and into the guide catheter. The loader 24 may be removed from the system by moving the introducer 25 and delivery catheter through a longitudinal slot 29 in the loader 24. The introducer 25 may be removed from the system by tearing or axially pulling apart the two halves 25a/25b of the introducer 25, as shown in FIG. 10D, such that the delivery catheter coupled to the ventricular partitioning device in the lumen of the guide catheter remains. In some embodiments, the sleeve 27 may remain on the delivery catheter or be removed. While two embodiments of an implant loading system are described above, any other suitable mechanism may be used and/or substituted by one skilled in the art to deliver a ventricular partitioning device to a heart of a patient.


In some embodiments, as shown in FIG. 11, a system for treating heart failure may include a ventricular partitioning device as described above, and a delivery catheter 23 having a proximal end and a distal end 23b. Further, a system for treating heart failure may include an expansion member 30 near the distal end 23b of the delivery catheter 23 configured to apply pressure to the support frame 3 of the ventricular partitioning device 1 to move the ventricular partitioning device 1 from a collapsed delivery configuration to an expanded deployed configuration, and a coupling element 31 configured to secure the expansion member 30 to the ventricular partitioning device 1 during deployment.


In some embodiments, the delivery catheter 23 may include a useable length between 120 cm and 170 cm, preferably 125 cm or 155 cm. In some embodiments, the delivery catheter 23 may include an outer diameter between 5 Fr and 14 Fr, preferably 10 Fr (3.3 mm).


In some embodiments, the expansion member 30 is coupled to the ventricular partitioning device 1 by a coupling element 31 proximal to the second ends 4b of the struts 4 of the support frame 3. In some embodiments, the coupling element 31 includes a helical screw, as shown in FIG. 11. Alternatively, in some embodiments, the coupling element 31 may include a sliding latch, lock, hook, or any other suitable mechanism. In some embodiments, the expansion member 30, for example a balloon, may be in fluid communication with a lumen in the shaft of the delivery catheter 23, such that inflation fluid may be delivered to the interior of the expansion member 30 to inflate the balloon. Alternatively, the balloon may be inflated by a gas, gel, or any other material. The balloon, once inflated, may include a diameter between 30 mm and 45 mm, preferably more than or equal to 32 mm.


In some embodiments, the ventricular partitioning device 1 radially expands in the ventricle once delivered to the ventricle. The expansion member 30, coupled to the ventricular partitioning device 1 by a coupling element 31, may be inflated at the distal end of the delivery catheter 23 to fully expand the ventricular partitioning device 1 within the ventricle and to facilitate anchoring the struts 4 of the ventricular partitioning device to an interior wall of the ventricle. Alternatively, in some embodiments, the ventricular partitioning device 1 may expand and anchor sufficiently without the use of the expansion member 30. In some embodiments, rotation of the delivery catheter 23 coupled to the ventricular partitioning device 1 may remove the expansion member 30 and delivery catheter 23 from the ventricular partitioning device 1.


In some embodiments, as shown in FIG. 12, a method of delivering a ventricular partitioning device comprises positioning with a delivery catheter an expandable partitioning device near an apex of a patient's ventricle, such that the expandable partitioning device includes a membrane coupled to a plurality of expandable struts S100; expanding an expansion member coupled to the partitioning device to apply pressure to the plurality of expandable struts to expand the partitioning device S110; and removing the expansion member from the partitioning device to deploy the partitioning device S120. In some embodiments, a method of delivering a ventricular partitioning device may further include loading the partitioning device into a guide catheter through a funnel and a sleeve. In some embodiments, a method of delivering a ventricular partitioning device may further include uncoupling a coupling element from the partitioning device to release the partitioning device from the delivery catheter. In some embodiments, a method of delivering a ventricular partitioning device may further include positioning a delivery sheath over the partitioning device to collapse the partitioning device for removal or redeployment of the partitioning device.


Manufacturing


As described above and as shown in FIGS. 6A and 6B, the struts 4 of the support frame 3 of a ventricular partitioning device are cut, for example, by a laser, from a metal tube, for example Nitinol. In some embodiments, a method for securing a membrane 5 to struts 4 of a support frame 3 includes providing the support frame 3 including a plurality of struts 4; positioning the support frame 3 within a first platen structure having a male shaping portion and a second platen structure having a female shaping portion; positioning a membrane, for example a polymeric sheet, on the support frame 3 within the first and second platen structures; pressing the first and second platen structures together; and heating the first and second platen structures housing the support frame 3 and the polymeric sheet to fuse the polymeric sheet to the support frame. In some embodiments, fusion may occur by heating and reforming of the thermoplastic material to the polymeric sheet.


In some embodiments, positioning the support frame 3 within a first platen structure includes slidably disposing tubes over the struts 4 of the support frame 3 and positioning the support frame 3 in the female platen structure on top of a membrane 5, such that the membrane 5 is sandwiched between the female platen and the support frame 3. In some embodiments, the tube disposed over the struts 4 of the support frame 3 may include a thermoplastic material or any other suitable material. In some embodiments, the membrane 5 includes a centrally located aperture configured to receive the hub 17 of the struts 4 of the support frame 3. In some embodiments, a second membrane may be positioned on top of the support frame, forming a bilaminar structure. A male platen may be positioned on the membrane 5 and support frame 3 on the female platen structure, such that the male and female platens are coupled and may be heated and pressed to couple the membrane 5 to the support structure 3. Alternatively, in some embodiments, the membrane 5 and support frame 3 may first be positioned in a male platen and the female platen may be secondarily positioned on the male platen and heated and pressed to couple the membrane 5 to the support structure 3.


In some embodiments, pressing and heating the male and female platens together may include pressing, clamping, compaction plus sintering, hot isostatic pressing, compression molding, and/or any other method known to one skilled in the art. The melting point of the thermoplastic material is lower than that of the membrane material, for example, ePTFE, such that the application of heat and pressure, as detailed above, is sufficient to melt the thermoplastic material but does not cause melting of the ePTFE membrane.


The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. Other embodiments may be utilized and derived therefrom, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is in fact disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other EMBODIMENTS not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.


When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.


Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.


Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.


Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.


Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.


As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.


Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.


The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.

Claims
  • 1. A method comprising: loading an expandable implant into a catheter for delivery to a heart utilizing an implant loading system, the implant loading system including: a funnel having a flared first end and a second end, wherein the flared first end comprises a tapering receptacle for receiving and collapsing the expandable implant, and a second portion at the second end comprises a lumen, the second end including a coupling element for removably coupling the funnel to a sleeve, anda sleeve configured to be removably coupled to the second end of the funnel and having a coupling element located in a center portion of the sleeve for mating with the coupling element at the second end of the funnel, the sleeve including a tubular portion distal to the coupling element of the sleeve that is configured to be positioned within the second portion of the funnel.
  • 2. The method of claim 1, wherein the lumen of the second portion has a first diameter, and the sleeve has a lumen with a second diameter that is less than the first diameter.
  • 3. The method of claim 2, wherein the tubular portion of the sleeve distal to the coupling element of the sleeve has the second diameter.
  • 4. The method of claim 1, wherein the tubular portion of the sleeve distal to the coupling element of the sleeve has a lumen that is configured to receive the expandable implant from the funnel.
  • 5. The method of claim 1, wherein the sleeve includes a tubular portion proximal to the coupling element of the sleeve.
  • 6. The method of claim 1, wherein the tubular portion of the sleeve distal to the coupling element of the sleeve extends distal from the second end of the funnel when the funnel and the sleeve are coupled together.
  • 7. The method of claim 1, wherein an interior of the funnel includes a smooth surface.
  • 8. The method of claim 1, wherein the coupling element of the sleeve is positioned upon an outer surface of the sleeve.
  • 9. The method of claim 1, wherein the coupling element of the funnel is positioned upon an interior surface of the funnel.
  • 10. The method of claim 1, further comprising: collapsing the expandable implant utilizing the funnel; andadvancing the expandable implant into the tubular portion of the sleeve.
  • 11. The method of claim 1, further comprising: collapsing the expandable implant utilizing the funnel; andadvancing the expandable implant into a lumen of the catheter.
  • 12. The method of claim 1, further comprising coupling the sleeve with the second end of the funnel.
  • 13. The method of claim 1, further comprising mating the coupling element of the sleeve with the coupling element at the second end of the funnel.
  • 14. The method of claim 1, further comprising positioning the tubular portion of the sleeve within the second portion of the funnel.
  • 15. The method of claim 1, further comprising uncoupling the sleeve from the second end of the funnel.
  • 16. The method of claim 1, further comprising expanding the expandable implant within the heart.
  • 17. The method of claim 1, further comprising releasing the expandable implant from the catheter.
  • 18. The method of claim 1, further comprising uncoupling a coupling element from the expandable implant to release the expandable implant from the catheter.
  • 19. The method of claim 1, wherein the expandable implant is for treating cardiac dysfunction.
  • 20. The method of claim 1, further comprising collapsing a support frame of the expandable implant utilizing the funnel.
Priority Claims (3)
Number Date Country Kind
201420564242.9 Sep 2014 CN national
201420564806.9 Sep 2014 CN national
201420564809.2 Sep 2014 CN national
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/997,634, filed Aug. 19, 2020, now U.S. Pat. No. 11,690,720, which is a continuation of U.S. patent application Ser. No. 15/506,562, filed Feb. 24, 2017, now U.S. Pat. No. 10,751,183, which claims priority to International Patent Application No. PCT/US2015/050827, filed Sep. 18, 2015, which claims priority to Chinese utility model patent application No. 201420564242.9, filed on Sep. 28, 2014 (titled “IMPLANT LOADING SYSTEMS”), which issued on Mar. 4, 2015 as ZL201420564242.9; Chinese utility model patent application No. 201420564809.2, filed on Sep. 28, 2014 (titled “EXPANDABLE DEVICES FOR INSERTING INTO A VENTRICLE OF A HEART TO TREAT HEART FAILURE”), which issued on Mar. 11, 2015 as ZL 2014205648092; and Chinese utility model patent application No. 201420564806.9, filed on Sep. 28, 2014 (titled “SYSTEMS OF EXPANDABLE DEVICES AND DELIVERY CATHETERS FOR TREATING CARDIAC DYSFUNCTION”), which issued on Feb. 25, 2015 as ZL 201420564806.9. Each of these applications is herein incorporated by reference in its entirety.

US Referenced Citations (1007)
Number Name Date Kind
3409013 Berry Nov 1968 A
3472230 Fogarty Oct 1969 A
3548417 Kisher Dec 1970 A
3587115 Shiley Jun 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3739402 Cooley et al. Jun 1973 A
3755823 Hancock Sep 1973 A
3874388 King et al. Apr 1975 A
4007743 Blake Feb 1977 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4079468 Liotta et al. Mar 1978 A
4106129 Carpentier et al. Aug 1978 A
4204283 Bellhouse et al. May 1980 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4340977 Brownlee et al. Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4425908 Simon Jan 1984 A
4453545 Inoue Jun 1984 A
4470157 Love Sep 1984 A
4477930 Totten et al. Oct 1984 A
4490859 Black et al. Jan 1985 A
4535483 Klawitter et al. Aug 1985 A
4536893 Parravicini Aug 1985 A
4553545 Maass et al. Nov 1985 A
4574803 Storz Mar 1986 A
4588404 Lapeyre May 1986 A
4592340 Boyles Jun 1986 A
4605407 Black et al. Aug 1986 A
4612011 Kautzky Sep 1986 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4643732 Pietsch et al. Feb 1987 A
4655771 Wallsten Apr 1987 A
4685446 Choy Aug 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz Mar 1988 A
4759758 Gabbay Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4829990 Thuroff et al. May 1989 A
4830003 Wolff et al. May 1989 A
4832055 Palestrant May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4865600 Carpentier et al. Sep 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4917089 Sideris Apr 1990 A
4922905 Strecker May 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4983165 Loiterman Jan 1991 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5104399 Lazarus Apr 1992 A
5108370 Walinsky Apr 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5192297 Hull Mar 1993 A
5192301 Kamiya et al. Mar 1993 A
5192314 Daskalakis Mar 1993 A
5232446 Arney Aug 1993 A
5258000 Gianturco Nov 1993 A
5266073 Wall Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5326371 Love et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5375612 Cottenceau et al. Dec 1994 A
5385156 Oliva Jan 1995 A
5389087 Miraki Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5411055 Kane May 1995 A
5411522 Trott May 1995 A
5411552 Andersen et al. May 1995 A
5415667 Frater May 1995 A
5425744 Fagan et al. Jun 1995 A
5433727 Sideris Jul 1995 A
5443446 Shturman Aug 1995 A
5451235 Lock et al. Sep 1995 A
5480424 Cox Jan 1996 A
5496277 Termin et al. Mar 1996 A
5500014 Quijano et al. Mar 1996 A
5527337 Stack et al. Jun 1996 A
5527338 Purdy Jun 1996 A
5545209 Roberts et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549621 Bessler et al. Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5551435 Sramek Sep 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5578069 Miner, II Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5599305 Hermann et al. Feb 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5634936 Linden et al. Jun 1997 A
5634942 Chevillon et al. Jun 1997 A
5639274 Fischell et al. Jun 1997 A
5647870 Kordis et al. Jul 1997 A
5665115 Cragg Sep 1997 A
5697382 Love et al. Dec 1997 A
5702343 Alferness Dec 1997 A
5702441 Zhou Dec 1997 A
5709707 Lock et al. Jan 1998 A
5716417 Girard et al. Feb 1998 A
5728068 Leone et al. Mar 1998 A
5746734 Dormandy, Jr. et al. May 1998 A
5749890 Shaknovich May 1998 A
5756476 Epstein et al. May 1998 A
5758664 Campbell et al. Jun 1998 A
5769812 Stevens et al. Jun 1998 A
5791231 Cohn et al. Aug 1998 A
5797849 Vesely et al. Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5800457 Gelbfish Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5800517 Anderson et al. Sep 1998 A
5829447 Stevens et al. Nov 1998 A
5833682 Amplatz et al. Nov 1998 A
5833698 Hinchliffe et al. Nov 1998 A
5836968 Simon et al. Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5843170 Ahn Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5860951 Eggers et al. Jan 1999 A
5861003 Latson et al. Jan 1999 A
5865730 Fox et al. Feb 1999 A
5865791 Whayne et al. Feb 1999 A
5871017 Mayer Feb 1999 A
5875782 Ferrari et al. Mar 1999 A
5876325 Mizuno et al. Mar 1999 A
5876449 Starck et al. Mar 1999 A
5879366 Shaw et al. Mar 1999 A
5882340 Yoon Mar 1999 A
5906619 Olson et al. May 1999 A
5910150 Saadat Jun 1999 A
5916145 Chu et al. Jun 1999 A
5924424 Stevens et al. Jul 1999 A
5925062 Purdy Jul 1999 A
5925063 Khosravi Jul 1999 A
5925076 Inoue Jul 1999 A
5928260 Chin et al. Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
5961440 Schweich, Jr. et al. Oct 1999 A
5961539 Northrup, III et al. Oct 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5984917 Fleischman et al. Nov 1999 A
6024096 Buckberg Feb 2000 A
6024756 Huebsch et al. Feb 2000 A
6027525 Suh et al. Feb 2000 A
6036720 Abrams et al. Mar 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6045497 Schweich, Jr. et al. Apr 2000 A
6059715 Schweich, Jr. et al. May 2000 A
6076013 Brennan et al. Jun 2000 A
6077214 Mortier et al. Jun 2000 A
6077218 Alferness Jun 2000 A
6086612 Jansen Jul 2000 A
6093199 Brown et al. Jul 2000 A
6095968 Snyders Aug 2000 A
6096347 Geddes et al. Aug 2000 A
6099832 Mickle et al. Aug 2000 A
6102887 Altman Aug 2000 A
6113631 Jansen Sep 2000 A
6125852 Stevens et al. Oct 2000 A
6132438 Fleischman et al. Oct 2000 A
6132473 Williams et al. Oct 2000 A
6142973 Carleton et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6155968 Wilk Dec 2000 A
6156027 West Dec 2000 A
6161543 Cox et al. Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6193731 Oppelt et al. Feb 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217585 Houser et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6221092 Koike et al. Apr 2001 B1
6221104 Buckberg et al. Apr 2001 B1
6230714 Alferness et al. May 2001 B1
6231561 Frazier et al. May 2001 B1
6231602 Carpentier et al. May 2001 B1
6245040 Inderbitzen et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6251093 Valley et al. Jun 2001 B1
6258021 Wilk Jul 2001 B1
6264630 Mickley et al. Jul 2001 B1
6267772 Mulhauser et al. Jul 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6290674 Roue et al. Sep 2001 B1
6296656 Bolduc et al. Oct 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goecoechea et al. Oct 2001 B1
6306141 Jervis Oct 2001 B1
6312446 Huebsch et al. Nov 2001 B1
6312465 Griffin et al. Nov 2001 B1
6328727 Frazier et al. Dec 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6343605 Lafontaine Feb 2002 B1
6348068 Campbell et al. Feb 2002 B1
6350277 Kocur Feb 2002 B1
6355052 Neuss et al. Mar 2002 B1
6358277 Duran Mar 2002 B1
6360749 Jayaraman Mar 2002 B1
6364896 Addis Apr 2002 B1
6379372 Dehdashtian et al. Apr 2002 B1
6387042 Herrero May 2002 B1
6406420 McCarthy et al. Jun 2002 B1
6419669 Frazier et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6436088 Frazier et al. Aug 2002 B2
6440164 Di Matteo et al. Aug 2002 B1
6450171 Buckberg et al. Sep 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6482146 Alferness et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6506204 Mazzocchi Jan 2003 B2
6508756 Kung et al. Jan 2003 B1
6511496 Huter et al. Jan 2003 B1
6527800 McGuckin, Jr. et al. Mar 2003 B1
6527979 Constantz Mar 2003 B2
6537198 Vidlund et al. Mar 2003 B1
6540782 Snyders Apr 2003 B1
6551303 Van Tassel et al. Apr 2003 B1
6569196 Vesely May 2003 B1
6572643 Gharibadeh Jun 2003 B1
6575959 Sarge et al. Jun 2003 B1
6582462 Andersen et al. Jun 2003 B1
6586414 Haque et al. Jul 2003 B2
6592608 Fisher et al. Jul 2003 B2
6605112 Moll et al. Aug 2003 B1
6610088 Gabbay Aug 2003 B1
6613013 Haarala et al. Sep 2003 B2
6622730 Ekvall et al. Sep 2003 B2
6629534 Goar et al. Oct 2003 B1
6645199 Jenkins et al. Nov 2003 B1
6652555 VanTassel et al. Nov 2003 B1
6676698 McGuckin, Jr. et al. Jan 2004 B2
6681773 Murphy et al. Jan 2004 B2
6685627 Jayaraman Feb 2004 B2
6695878 McGuckin, Jr. et al. Feb 2004 B2
6702763 Murphy et al. Mar 2004 B2
6712836 Berg et al. Mar 2004 B1
6716207 Farnholtz Apr 2004 B2
6729356 Baker et al. May 2004 B1
6730108 Van Tassel et al. May 2004 B2
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6746422 Noriega et al. Jun 2004 B1
6749560 Konstorum et al. Jun 2004 B1
6767362 Schreck Jul 2004 B2
6776754 Wilk Aug 2004 B1
6780200 Jansen Aug 2004 B2
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6830584 Seguin Dec 2004 B1
6852076 Nikolic et al. Feb 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6887192 Whayne et al. May 2005 B1
6893460 Spenser et al. May 2005 B2
6908481 Cribier Jun 2005 B2
6951534 Girard et al. Oct 2005 B2
6959711 Murphy et al. Nov 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6994093 Murphy et al. Feb 2006 B2
7018406 Seguin et al. Mar 2006 B2
7144363 Pai et al. Dec 2006 B2
7172551 Leasure Feb 2007 B2
7175660 Cartledge et al. Feb 2007 B2
7186265 Sharkawy et al. Mar 2007 B2
7192440 Andreas et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7279007 Nikolic et al. Oct 2007 B2
7303526 Sharkey et al. Dec 2007 B2
7318278 Zhang et al. Jan 2008 B2
7320665 Vijay Jan 2008 B2
7374571 Pease et al. May 2008 B2
7381210 Zarbatany et al. Jun 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7399271 Khairkhahan et al. Jul 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7462191 Spenser et al. Dec 2008 B2
7485088 Murphy et al. Feb 2009 B2
7510575 Spenser et al. Mar 2009 B2
7524330 Berreklouw Apr 2009 B2
7530253 Spenser et al. May 2009 B2
7530998 Starkey May 2009 B1
7553324 Andreas et al. Jun 2009 B2
7569062 Kuehn et al. Aug 2009 B1
7579381 Dove Aug 2009 B2
7582051 Khairkhahan et al. Sep 2009 B2
7585321 Cribier Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7674222 Nikolic et al. Mar 2010 B2
7704222 Wilk et al. Apr 2010 B2
7736327 Wilk et al. Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7753949 Lamphere et al. Jul 2010 B2
7758491 Buckner et al. Jul 2010 B2
7762943 Khairkhahan Jul 2010 B2
7806919 Bloom et al. Oct 2010 B2
7824325 Dubi Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7837727 Goetz et al. Nov 2010 B2
7862500 Khairkhahan et al. Jan 2011 B2
7887477 Nikolic et al. Feb 2011 B2
7892281 Seguin et al. Feb 2011 B2
7897086 Khairkhahan et al. Mar 2011 B2
7914569 Nguyen et al. Mar 2011 B2
7914575 Guyenot et al. Mar 2011 B2
7938767 Evans et al. May 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7972378 Tabor et al. Jul 2011 B2
7976455 Khairkhahan Jul 2011 B2
7981151 Rowe Jul 2011 B2
7993258 Feld et al. Aug 2011 B2
7993392 Righini et al. Aug 2011 B2
7993394 Hariton et al. Aug 2011 B2
8007992 Tian et al. Aug 2011 B2
8016877 Seguin et al. Sep 2011 B2
8029556 Rowe Oct 2011 B2
8052750 Tuval et al. Nov 2011 B2
8070800 Lock et al. Dec 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8075615 Eberhardt et al. Dec 2011 B2
8080054 Rowe Dec 2011 B2
8092520 Quadri Jan 2012 B2
8092521 Figulla et al. Jan 2012 B2
8109996 Stacchino et al. Feb 2012 B2
8118866 Herrmann et al. Feb 2012 B2
8136218 Millwee et al. Mar 2012 B2
8137398 Tuval et al. Mar 2012 B2
8157852 Bloom et al. Apr 2012 B2
8167932 Bourang May 2012 B2
8167934 Styrc et al. May 2012 B2
8182530 Huber May 2012 B2
8192478 Khairkhahan et al. Jun 2012 B2
8206437 Bonhoeffer et al. Jun 2012 B2
8216174 Wilk et al. Jul 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8219229 Cao et al. Jul 2012 B2
8220121 Hendriksen et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8246671 Khairkhahan Aug 2012 B2
8246675 Zegdi Aug 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8257428 Khairkhahan et al. Sep 2012 B2
8287584 Salahieh et al. Oct 2012 B2
8313525 Tuval et al. Nov 2012 B2
8317858 Straubinger et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8337541 Quadri et al. Dec 2012 B2
8353953 Giannetti et al. Jan 2013 B2
8377114 Khairkhahan et al. Feb 2013 B2
8382653 Dubi et al. Feb 2013 B2
8388672 Khairkhahan et al. Mar 2013 B2
8398537 Khairkhahan et al. Mar 2013 B2
8398704 Straubinger et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414644 Quadri et al. Apr 2013 B2
8414645 Dwork et al. Apr 2013 B2
8416643 Magee Apr 2013 B2
8444689 Zhang May 2013 B2
8449599 Chau et al. May 2013 B2
8454685 Hariton et al. Jun 2013 B2
8460368 Taylor et al. Jun 2013 B2
8460370 Zakay Jun 2013 B2
8470023 Eidenschink et al. Jun 2013 B2
8470028 Thornton et al. Jun 2013 B2
8475521 Suri et al. Jul 2013 B2
8475523 Duffy Jul 2013 B2
8479380 Malewicz et al. Jul 2013 B2
8491650 Wiemeyer et al. Jul 2013 B2
8500622 Lipperman et al. Aug 2013 B2
8500733 Watson Aug 2013 B2
8500790 Khairkhahan Aug 2013 B2
8500795 Khairkhahan et al. Aug 2013 B2
8500798 Rowe et al. Aug 2013 B2
8511244 Holecek et al. Aug 2013 B2
8512401 Murray, III et al. Aug 2013 B2
8518096 Nelson Aug 2013 B2
8518106 Duffy et al. Aug 2013 B2
8529430 Nikolic et al. Sep 2013 B2
8562663 Mearns et al. Oct 2013 B2
8579963 Tabor Nov 2013 B2
8579964 Lane et al. Nov 2013 B2
8591570 Revuelta et al. Nov 2013 B2
8617236 Paul et al. Dec 2013 B2
8640521 Righini et al. Feb 2014 B2
8647381 Essinger et al. Feb 2014 B2
8652145 Maimon et al. Feb 2014 B2
8652201 Oberti et al. Feb 2014 B2
8652202 Alon et al. Feb 2014 B2
8652203 Quadri et al. Feb 2014 B2
8657873 Khairkhahan et al. Feb 2014 B2
8668733 Haug et al. Mar 2014 B2
8672827 Nikolic et al. Mar 2014 B2
8679174 Ottma et al. Mar 2014 B2
8679404 Liburd et al. Mar 2014 B2
8685086 Navia et al. Apr 2014 B2
8721708 Seguin et al. May 2014 B2
8721714 Kelley May 2014 B2
8728154 Alkhatib May 2014 B2
8728155 Montorfano et al. May 2014 B2
8740974 Lambrecht et al. Jun 2014 B2
8740976 Tran et al. Jun 2014 B2
8747458 Tuval et al. Jun 2014 B2
8747459 Nguyen et al. Jun 2014 B2
8758432 Solem Jun 2014 B2
8764818 Gregg Jul 2014 B2
8764848 Callaghan et al. Jul 2014 B2
8771344 Tran et al. Jul 2014 B2
8778020 Gregg et al. Jul 2014 B2
8784337 Voeller et al. Jul 2014 B2
8784478 Tuval et al. Jul 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8790242 Kermode et al. Jul 2014 B2
8790387 Nguyen et al. Jul 2014 B2
8795357 Yohanan et al. Aug 2014 B2
8808356 Braido et al. Aug 2014 B2
8827892 Nikolic et al. Sep 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8828079 Thielen et al. Sep 2014 B2
8834564 Tuval et al. Sep 2014 B2
8858620 Salahieh et al. Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8870950 Hacohen Oct 2014 B2
8876893 Dwork et al. Nov 2014 B2
8911455 Quadri et al. Dec 2014 B2
8926693 Duffy et al. Jan 2015 B2
8926694 Costello Jan 2015 B2
8931159 Hillukka Jan 2015 B2
8939960 Rosenman et al. Jan 2015 B2
8945209 Bonyuet et al. Feb 2015 B2
8961593 Bonhoeffer et al. Feb 2015 B2
8961595 Alkhatib Feb 2015 B2
8974524 Yeung et al. Mar 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8986375 Garde et al. Mar 2015 B2
8998980 Shipley et al. Apr 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011521 Haug et al. Apr 2015 B2
9011523 Seguin Apr 2015 B2
9011524 Eberhardt Apr 2015 B2
9017394 Khairkhahan Apr 2015 B2
9028545 Taylor May 2015 B2
9034032 McLean et al. May 2015 B2
9039597 Kermode et al. May 2015 B2
9055937 Rowe et al. Jun 2015 B2
9066801 Kovalsky et al. Jun 2015 B2
9078660 Boutillette et al. Jul 2015 B2
9078749 Lutter et al. Jul 2015 B2
9078751 Naor Jul 2015 B2
9125738 Figulla et al. Sep 2015 B2
9173737 Hill et al. Nov 2015 B2
9180004 Alkhatib Nov 2015 B2
9186249 Rolando et al. Nov 2015 B2
9192496 Robinson Nov 2015 B2
9277990 Klima et al. Mar 2016 B2
9277993 Gamarra et al. Mar 2016 B2
9289291 Gorman, III et al. Mar 2016 B2
9295551 Straubinger et al. Mar 2016 B2
9332992 Alexander May 2016 B2
9332993 Kermode et al. May 2016 B2
9364327 Kermode et al. Jun 2016 B2
9445897 Bishop et al. Sep 2016 B2
9456877 Weitzner et al. Oct 2016 B2
9592123 Nikolic et al. Mar 2017 B2
9681968 Goetz et al. Jun 2017 B2
9687345 Rabito et al. Jun 2017 B2
9700329 Metzger et al. Jul 2017 B2
9700411 Klima et al. Jul 2017 B2
9724083 Quadri et al. Aug 2017 B2
9730790 Quadri et al. Aug 2017 B2
9730791 Ratz et al. Aug 2017 B2
9795479 Lim et al. Oct 2017 B2
9833313 Board et al. Dec 2017 B2
9861473 Lafontaine Jan 2018 B2
9861476 Salahieh et al. Jan 2018 B2
9861477 Backus et al. Jan 2018 B2
9867698 Kovalsky et al. Jan 2018 B2
9877830 Lim et al. Jan 2018 B2
9889029 Li et al. Feb 2018 B2
9895225 Rolando et al. Feb 2018 B2
9925045 Creaven et al. Mar 2018 B2
10004599 Rabito et al. Jun 2018 B2
10117744 Ratz et al. Nov 2018 B2
10179044 Ratz et al. Jan 2019 B2
10219897 Essinger et al. Mar 2019 B2
10307147 Khairkhahan et al. Jun 2019 B2
10350065 Quadri Jul 2019 B2
10350066 Cooper et al. Jul 2019 B2
10376363 Quadri et al. Aug 2019 B2
10555809 Hastings et al. Feb 2020 B2
10575951 Johnson et al. Mar 2020 B2
10583000 Ratz et al. Mar 2020 B2
10639146 Quadri et al. May 2020 B2
10695177 Hariton et al. Jun 2020 B2
10758344 Hariton et al. Sep 2020 B2
11406499 Zhang et al. Aug 2022 B2
11452598 Essinger et al. Sep 2022 B2
11672658 Hariton et al. Jun 2023 B2
11690720 Alexander Jul 2023 B2
11701225 Hammer et al. Jul 2023 B2
11864771 Alexander Jan 2024 B2
11903829 Ma et al. Feb 2024 B1
20010014800 Frazier et al. Aug 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20020019580 Lau et al. Feb 2002 A1
20020026092 Buckberg et al. Feb 2002 A1
20020028981 Lau et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020045929 Diaz Apr 2002 A1
20020052644 Shaolian et al. May 2002 A1
20020055767 Forde et al. May 2002 A1
20020055775 Carpentier et al. May 2002 A1
20020056461 Jayaraman May 2002 A1
20020111647 Khairkhahan et al. Aug 2002 A1
20020133227 Murphy et al. Sep 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020169359 McCarthy et al. Nov 2002 A1
20020169360 Taylor et al. Nov 2002 A1
20020173842 Buchanan Nov 2002 A1
20020183604 Gowda et al. Dec 2002 A1
20020183827 Derus et al. Dec 2002 A1
20020188170 Santamore et al. Dec 2002 A1
20030012337 Fewster et al. Jan 2003 A1
20030045896 Murphy et al. Mar 2003 A1
20030050682 Sharkey et al. Mar 2003 A1
20030050685 Nikolic et al. Mar 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030078671 Lesniak et al. Apr 2003 A1
20030100939 Yodfat et al. May 2003 A1
20030105384 Sharkey et al. Jun 2003 A1
20030105517 White et al. Jun 2003 A1
20030109770 Sharkey et al. Jun 2003 A1
20030120333 Ouriel et al. Jun 2003 A1
20030120337 Van Tassel et al. Jun 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030135230 Massey et al. Jul 2003 A1
20030149333 Alferness Aug 2003 A1
20030149422 Muller Aug 2003 A1
20030158570 Ferrazzi Aug 2003 A1
20030158597 Quiachon et al. Aug 2003 A1
20030176914 Rabkin et al. Sep 2003 A1
20030181928 Vidlund et al. Sep 2003 A1
20030181942 Sutton et al. Sep 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030220667 van der Burg et al. Nov 2003 A1
20030220683 Minasian et al. Nov 2003 A1
20030225445 Derus et al. Dec 2003 A1
20030229265 Girard et al. Dec 2003 A1
20040002626 Feld et al. Jan 2004 A1
20040034366 van der Burg et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040044361 Frazier et al. Mar 2004 A1
20040049210 VanTassel et al. Mar 2004 A1
20040054394 Lee Mar 2004 A1
20040064014 Melvin et al. Apr 2004 A1
20040092858 Wilson et al. May 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122090 Lipton Jun 2004 A1
20040127935 VanTassel et al. Jul 2004 A1
20040133062 Pai et al. Jul 2004 A1
20040133263 Dusbabek et al. Jul 2004 A1
20040133273 Cox Jul 2004 A1
20040136992 Burton et al. Jul 2004 A1
20040172042 Suon et al. Sep 2004 A1
20040186511 Stephens et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215230 Frazier et al. Oct 2004 A1
20040215325 Penn et al. Oct 2004 A1
20040220610 Kreidler et al. Nov 2004 A1
20040225353 McGuckin et al. Nov 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040243170 Suresh et al. Dec 2004 A1
20040260331 D'Aquanni et al. Dec 2004 A1
20040260346 Overall et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040267086 Anstadt et al. Dec 2004 A1
20040267378 Gazi et al. Dec 2004 A1
20050007031 Hyder Jan 2005 A1
20050015109 Lichtenstein Jan 2005 A1
20050033398 Seguin Feb 2005 A1
20050038470 van der Burg et al. Feb 2005 A1
20050043708 Gleeson et al. Feb 2005 A1
20050065548 Marino et al. Mar 2005 A1
20050075727 Wheatley Apr 2005 A1
20050085826 Nair et al. Apr 2005 A1
20050090887 Pryor Apr 2005 A1
20050096498 Houser et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050107872 Mensah et al. May 2005 A1
20050113811 Houser et al. May 2005 A1
20050113861 Corcoran et al. May 2005 A1
20050124849 Barbut et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050142180 Bisgaier et al. Jun 2005 A1
20050154252 Sharkey et al. Jul 2005 A1
20050159811 Lane Jul 2005 A1
20050177180 Kaganov et al. Aug 2005 A1
20050182486 Gabbay Aug 2005 A1
20050187620 Pai et al. Aug 2005 A1
20050197716 Sharkey et al. Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050216052 Mazzocchi et al. Sep 2005 A1
20050216079 MaCoviak Sep 2005 A1
20050228434 Amplatz et al. Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050256532 Nayak et al. Nov 2005 A1
20050277981 Maahs et al. Dec 2005 A1
20050277983 Saadat et al. Dec 2005 A1
20050283218 Williams Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060014998 Sharkey et al. Jan 2006 A1
20060019888 Zhou Jan 2006 A1
20060020327 Lashinski et al. Jan 2006 A1
20060025800 Suresh Feb 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060030881 Sharkey et al. Feb 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060063970 Raman et al. Mar 2006 A1
20060069430 Rahdert et al. Mar 2006 A9
20060079736 Chin et al. Apr 2006 A1
20060095115 Bladillah et al. May 2006 A1
20060116692 Ward Jun 2006 A1
20060135947 Soltesz et al. Jun 2006 A1
20060136043 Cully et al. Jun 2006 A1
20060142837 Haverkost et al. Jun 2006 A1
20060149350 Patel et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060167334 Anstadt et al. Jul 2006 A1
20060173524 Salahieh et al. Aug 2006 A1
20060173537 Yang et al. Aug 2006 A1
20060195134 Crittenden Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060199995 Vijay Sep 2006 A1
20060212110 Osborne et al. Sep 2006 A1
20060229491 Sharkey et al. Oct 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060241334 Dubi et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060259124 Matsuoka et al. Nov 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060264980 Khairkhahan et al. Nov 2006 A1
20060276684 Speziali Dec 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060281965 Khairkhahan et al. Dec 2006 A1
20060293745 Carpentier et al. Dec 2006 A1
20070005131 Taylor Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070027534 Bergheim et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070050021 Johnson Mar 2007 A1
20070066863 Rafiee et al. Mar 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070100432 Case et al. May 2007 A1
20070100439 Cangialosi et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070129753 Quinn et al. Jun 2007 A1
20070129794 Realyvasquez Jun 2007 A1
20070135826 Zaver et al. Jun 2007 A1
20070135889 Moore et al. Jun 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070156224 Cioanta et al. Jul 2007 A1
20070161846 Nikolic et al. Jul 2007 A1
20070162048 Quinn et al. Jul 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070213578 Khairkhahan et al. Sep 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070213815 Khairkhahan et al. Sep 2007 A1
20070255394 Ryan Nov 2007 A1
20070270931 Leanna et al. Nov 2007 A1
20070270943 Solem et al. Nov 2007 A1
20080015717 Griffin et al. Jan 2008 A1
20080021546 Patz et al. Jan 2008 A1
20080045778 Lichtenstein et al. Feb 2008 A1
20080065011 Marchand et al. Mar 2008 A1
20080071133 Dubi Mar 2008 A1
20080071134 Dubi et al. Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082164 Friedman Apr 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080097581 Shanley Apr 2008 A1
20080114442 Mitchell et al. May 2008 A1
20080125853 Bailey et al. May 2008 A1
20080147179 Cai et al. Jun 2008 A1
20080147183 Styrc Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221384 Chi Sing et al. Sep 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080228205 Sharkey et al. Sep 2008 A1
20080228254 Ryan Sep 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080281411 Berreklouw Nov 2008 A1
20080293996 Evans et al. Nov 2008 A1
20080300672 Kassab et al. Dec 2008 A1
20080319254 Nikolic et al. Dec 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090054723 Khairkhahan et al. Feb 2009 A1
20090054968 Bonhoeffer et al. Feb 2009 A1
20090054974 McGuckin, Jr. et al. Feb 2009 A1
20090062601 Khairkhahan et al. Mar 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090112050 Farnan et al. Apr 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157175 Benichou Jun 2009 A1
20090164005 Dove et al. Jun 2009 A1
20090171432 Von Segesser et al. Jul 2009 A1
20090171447 Von Segesser et al. Jul 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090182413 Burkart et al. Jul 2009 A1
20090187063 Khairkhahan Jul 2009 A1
20090188964 Orlov Jul 2009 A1
20090216310 Straubinger et al. Aug 2009 A1
20090216313 Straubinger et al. Aug 2009 A1
20090216322 Le et al. Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090228093 Taylor et al. Sep 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090270972 Lane Oct 2009 A1
20090276027 Glynn Nov 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281618 Hill et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287296 Manasse Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20090292350 Eberhardt et al. Nov 2009 A1
20090306768 Quadri Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20100016958 St. Goar et al. Jan 2010 A1
20100022821 Dubi et al. Jan 2010 A1
20100030256 Dubrul et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100057185 Melsheimer et al. Mar 2010 A1
20100069852 Kelley Mar 2010 A1
20100114305 Kang et al. May 2010 A1
20100121132 Nikolic et al. May 2010 A1
20100131054 Tuval et al. May 2010 A1
20100137979 Tuval et al. Jun 2010 A1
20100174362 Straubinger et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249894 Oba et al. Sep 2010 A1
20100249911 Alkhatib Sep 2010 A1
20100256723 Murray Oct 2010 A1
20100262231 Tuval et al. Oct 2010 A1
20100274227 Khairkhahan et al. Oct 2010 A1
20100305685 Millwee et al. Dec 2010 A1
20100312333 Navia et al. Dec 2010 A1
20110015616 Straubinger et al. Jan 2011 A1
20110015729 Jimenez et al. Jan 2011 A1
20110021864 Criscione et al. Jan 2011 A1
20110046712 Melsheimer et al. Feb 2011 A1
20110092761 Almog et al. Apr 2011 A1
20110098525 Kermode et al. Apr 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110178362 Evans et al. Jul 2011 A1
20110178597 Navia et al. Jul 2011 A9
20110208290 Straubinger et al. Aug 2011 A1
20110208297 Tuval et al. Aug 2011 A1
20110208298 Tuval et al. Aug 2011 A1
20110224785 Hacohen Sep 2011 A1
20110238159 Guyenot et al. Sep 2011 A1
20110257461 Lipperman et al. Oct 2011 A1
20110264196 Savage et al. Oct 2011 A1
20110264198 Murray, III et al. Oct 2011 A1
20110264204 Khairkhahan Oct 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20110313515 Quadri et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120022639 Hacohen et al. Jan 2012 A1
20120035722 Tuval Feb 2012 A1
20120041257 Stankus et al. Feb 2012 A1
20120041550 Salahieh et al. Feb 2012 A1
20120046741 Tuval et al. Feb 2012 A1
20120046742 Tuval et al. Feb 2012 A1
20120078360 Rafiee Mar 2012 A1
20120101570 Tuval et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120123529 Levi et al. May 2012 A1
20120185039 Tuval et al. Jul 2012 A1
20120197386 Von Segesser et al. Aug 2012 A1
20120209374 Bonhoeffer et al. Aug 2012 A1
20120215303 Quadri et al. Aug 2012 A1
20120245604 Tegzes Sep 2012 A1
20120271398 Essinger et al. Oct 2012 A1
20120283823 Bonhoeffer et al. Nov 2012 A1
20120290062 McNamara et al. Nov 2012 A1
20120296418 Bonyuet et al. Nov 2012 A1
20120310328 Olson et al. Dec 2012 A1
20120310336 Figulla et al. Dec 2012 A1
20120330408 Hillukka et al. Dec 2012 A1
20130006294 Kashkarov et al. Jan 2013 A1
20130035759 Gross et al. Feb 2013 A1
20130073035 Tuval et al. Mar 2013 A1
20130079869 Straubinger et al. Mar 2013 A1
20130090677 Evans et al. Apr 2013 A1
20130165735 Khairkhahan et al. Jun 2013 A1
20130190861 Chau et al. Jul 2013 A1
20130190862 Pintor et al. Jul 2013 A1
20130197622 Mitra et al. Aug 2013 A1
20130211508 Lane et al. Aug 2013 A1
20130253635 Straubinger et al. Sep 2013 A1
20130253642 Brecker Sep 2013 A1
20130274595 Kermode et al. Oct 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130331929 Mitra et al. Dec 2013 A1
20130338766 Hastings et al. Dec 2013 A1
20130345786 Behan Dec 2013 A1
20140018912 Delaloye et al. Jan 2014 A1
20140025163 Padala et al. Jan 2014 A1
20140039611 Lane et al. Feb 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140100651 Kheradvar et al. Apr 2014 A1
20140163668 Rafiee Jun 2014 A1
20140172077 Bruchman et al. Jun 2014 A1
20140172083 Bruchman et al. Jun 2014 A1
20140180271 Johnson et al. Jun 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140207231 Hacohen et al. Jul 2014 A1
20140214157 Bortlein et al. Jul 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140222139 Nguyen et al. Aug 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140222144 Eberhardt et al. Aug 2014 A1
20140243966 Garde et al. Aug 2014 A1
20140257467 Lane et al. Sep 2014 A1
20140277390 Ratz et al. Sep 2014 A1
20140277412 Bortlein et al. Sep 2014 A1
20140277422 Ratz et al. Sep 2014 A1
20140277426 Dakin et al. Sep 2014 A1
20140277427 Ratz et al. Sep 2014 A1
20140296624 Kermode et al. Oct 2014 A1
20140296973 Bergheim et al. Oct 2014 A1
20140296975 Tegels et al. Oct 2014 A1
20140303719 Cox et al. Oct 2014 A1
20140309728 Dehdashtian et al. Oct 2014 A1
20140324160 Benichou et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140330368 Gloss et al. Nov 2014 A1
20140330371 Gloss et al. Nov 2014 A1
20140330372 Weston et al. Nov 2014 A1
20140331475 Duffy Nov 2014 A1
20140336754 Gurskis et al. Nov 2014 A1
20140343356 Nikolic et al. Nov 2014 A1
20140343669 Lane et al. Nov 2014 A1
20140343670 Bakis et al. Nov 2014 A1
20140345109 Grant et al. Nov 2014 A1
20140350666 Righini Nov 2014 A1
20140350668 Delaloye et al. Nov 2014 A1
20140358223 Rafiee et al. Dec 2014 A1
20140364939 Deshmukh et al. Dec 2014 A1
20140364941 Edmiston et al. Dec 2014 A1
20140364943 Conklin Dec 2014 A1
20140371789 Hariton et al. Dec 2014 A1
20140371842 Marquez et al. Dec 2014 A1
20140371844 Dale et al. Dec 2014 A1
20140371847 Madrid et al. Dec 2014 A1
20140371848 Murray et al. Dec 2014 A1
20150005863 Para Jan 2015 A1
20150018944 O'Connell et al. Jan 2015 A1
20150039083 Rafiee Feb 2015 A1
20150142103 Vidlund May 2015 A1
20150148731 McNamara et al. May 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150196390 Ma et al. Jul 2015 A1
20150209141 Braido et al. Jul 2015 A1
20150209144 Khairkhahan Jul 2015 A1
20150265405 Boutillette et al. Sep 2015 A1
20150272737 Dale et al. Oct 2015 A1
20150297346 Duffy et al. Oct 2015 A1
20150297381 Essinger et al. Oct 2015 A1
20150335429 Morriss et al. Nov 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150359629 Ganesan et al. Dec 2015 A1
20160000591 Lei et al. Jan 2016 A1
20160030169 Shahriari Feb 2016 A1
20160030170 Alkhatib et al. Feb 2016 A1
20160030171 Quijano et al. Feb 2016 A1
20160038281 Delaloye et al. Feb 2016 A1
20160074160 Christianson et al. Mar 2016 A1
20160106537 Christianson et al. Apr 2016 A1
20160113765 Ganesan et al. Apr 2016 A1
20160113768 Ganesan et al. Apr 2016 A1
20160143732 Glimsdale May 2016 A1
20160158010 Lim et al. Jun 2016 A1
20160166383 Lim et al. Jun 2016 A1
20160184097 Lim et al. Jun 2016 A1
20160199206 Lim et al. Jul 2016 A1
20160213473 Hacohen et al. Jul 2016 A1
20160235529 Ma et al. Aug 2016 A1
20160262892 Kermode et al. Sep 2016 A1
20160279386 Dale et al. Sep 2016 A1
20160302924 Boutillette et al. Oct 2016 A1
20160310267 Zeng et al. Oct 2016 A1
20170128209 Morriss et al. May 2017 A1
20170216023 Lane et al. Aug 2017 A1
20170216575 Asleson et al. Aug 2017 A1
20170258614 Griffin Sep 2017 A1
20170325954 Perszyk Nov 2017 A1
20170348096 Anderson Dec 2017 A1
20170367821 Landon et al. Dec 2017 A1
20170367823 Hariton et al. Dec 2017 A1
20180021129 Peterson et al. Jan 2018 A1
20180055629 Oba et al. Mar 2018 A1
20180055636 Valencia et al. Mar 2018 A1
20180085218 Eidenschink Mar 2018 A1
20180110534 Gavala et al. Apr 2018 A1
20180116790 Ratz et al. May 2018 A1
20190008639 Landon et al. Jan 2019 A1
20190008640 Cooper et al. Jan 2019 A1
20190060072 Zeng Feb 2019 A1
20190262129 Cooper et al. Aug 2019 A1
20200000579 Manash et al. Jan 2020 A1
20200108225 Jamal et al. Apr 2020 A1
20200345494 Srinimukesh et al. Nov 2020 A1
20200352718 Rowe et al. Nov 2020 A1
20210145576 Becerra et al. May 2021 A1
20210378817 Nia et al. Dec 2021 A1
20210386544 Cooper et al. Dec 2021 A1
20220142777 Scheinblum et al. May 2022 A1
20220287836 Landon et al. Sep 2022 A1
20220346993 Srinimukesh et al. Nov 2022 A1
20230000624 Okabe et al. Jan 2023 A1
20230200980 Peterson et al. Jun 2023 A1
20230218391 Dass et al. Jul 2023 A1
20230380963 Kaufman et al. Nov 2023 A1
20230390052 Okafor et al. Dec 2023 A1
20230404753 Luong et al. Dec 2023 A1
20240008978 Nawalakhe et al. Jan 2024 A1
Foreign Referenced Citations (155)
Number Date Country
2304325 Oct 2000 CA
204169959 Feb 2015 CN
2246526 Mar 1973 DE
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10010074 Oct 2001 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
102006052564 Dec 2007 DE
0103546 Mar 1984 EP
0144167 Jun 1985 EP
0592410 Apr 1994 EP
0597967 May 1994 EP
0850607 Jul 1998 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
1171059 Jan 2002 EP
1239901 Sep 2002 EP
1255510 Nov 2002 EP
1259194 Nov 2002 EP
1369098 Dec 2003 EP
1469797 Oct 2004 EP
1472996 Nov 2004 EP
1474032 Nov 2004 EP
1570809 Sep 2005 EP
1653888 May 2006 EP
1849440 Oct 2007 EP
1935377 Jun 2008 EP
2124826 Dec 2009 EP
2168536 Mar 2010 EP
2413842 Feb 2012 EP
2446915 May 2012 EP
2082690 Jun 2012 EP
2745805 Jun 2014 EP
2749254 Jul 2014 EP
2750630 Jul 2014 EP
2777616 Sep 2014 EP
2777617 Sep 2014 EP
2918249 Sep 2015 EP
2948103 Dec 2015 EP
2967858 Jan 2016 EP
3037064 Jun 2016 EP
3046511 Jul 2016 EP
3057541 Aug 2016 EP
3075354 Oct 2016 EP
3139864 Mar 2017 EP
3142603 Mar 2017 EP
3184083 Jun 2017 EP
3294220 Mar 2018 EP
3417813 Dec 2018 EP
3570779 Nov 2019 EP
2788217 Jul 2000 FR
1264471 Feb 1972 GB
1315844 May 1973 GB
2056023 Mar 1981 GB
2398245 Aug 2004 GB
1271508 Nov 1986 SU
9116041 Oct 1991 WO
9117720 Nov 1991 WO
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9724080 Jul 1997 WO
9803213 Jan 1998 WO
9829057 Jul 1998 WO
9933414 Jul 1999 WO
9940964 Aug 1999 WO
9947075 Sep 1999 WO
0041652 Jul 2000 WO
0047139 Aug 2000 WO
0061034 Oct 2000 WO
0236048 May 2002 WO
0245710 Jun 2002 WO
02087481 Nov 2002 WO
03047468 Jun 2003 WO
03092554 Nov 2003 WO
03103743 Dec 2003 WO
2004012629 Feb 2004 WO
2004030569 Apr 2004 WO
2005011534 Feb 2005 WO
2005034812 Apr 2005 WO
2005087140 Sep 2005 WO
2005102015 Nov 2005 WO
2006014233 Feb 2006 WO
2006034008 Mar 2006 WO
2006085225 Aug 2006 WO
2006108090 Oct 2006 WO
2006111391 Oct 2006 WO
2006138173 Dec 2006 WO
2007025028 Mar 2007 WO
2008005405 Jan 2008 WO
2008010792 Jan 2008 WO
2008035337 Mar 2008 WO
2008125153 Oct 2008 WO
2008147964 Dec 2008 WO
2008150529 Dec 2008 WO
2009024859 Feb 2009 WO
2009026563 Feb 2009 WO
2009042196 Apr 2009 WO
2009091509 Jul 2009 WO
2009094500 Jul 2009 WO
2010005524 Jan 2010 WO
2010008549 Jan 2010 WO
2010121076 Oct 2010 WO
2011002996 Jan 2011 WO
2011041422 Apr 2011 WO
2011081997 Jul 2011 WO
2012008459 Jan 2012 WO
2012032187 Mar 2012 WO
2012095455 Jul 2012 WO
2012099418 Jul 2012 WO
2013005878 Jan 2013 WO
2013028387 Feb 2013 WO
2013065036 May 2013 WO
2013106585 Jul 2013 WO
2013128461 Sep 2013 WO
2014009213 Jan 2014 WO
2014018432 Jan 2014 WO
2014079291 May 2014 WO
2014141209 Sep 2014 WO
2014145338 Sep 2014 WO
2014149865 Sep 2014 WO
2014163706 Oct 2014 WO
2014194178 Dec 2014 WO
2015004624 Jan 2015 WO
2015004625 Jan 2015 WO
2015057407 Apr 2015 WO
2015077274 May 2015 WO
2016002189 Jan 2016 WO
2016004137 Jan 2016 WO
2016016899 Feb 2016 WO
2017006510 Jan 2017 WO
2017035487 Mar 2017 WO
2018000333 Jan 2018 WO
2018213209 Nov 2018 WO
2022002054 Jan 2022 WO
2023006048 Feb 2023 WO
2023076103 May 2023 WO
2023081236 May 2023 WO
2023091769 May 2023 WO
2023096804 Jun 2023 WO
2023154250 Aug 2023 WO
2023196150 Oct 2023 WO
2023244454 Dec 2023 WO
2023244767 Dec 2023 WO
2023250114 Dec 2023 WO
2024001789 Jan 2024 WO
2024003620 Jan 2024 WO
2024007575 Jan 2024 WO
2024009540 Jan 2024 WO
2024010739 Jan 2024 WO
2024030520 Feb 2024 WO
Non-Patent Literature Citations (81)
Entry
Andersen, et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.”European Heart Journal (1992), 13, 704-708
Andersen, Henning Rud, “History of Percutaneous Aortic Valve Prosthesis,” Herz 34 2009 Nr. 5, Urban & Vogel, pp. 343-346, Skejby University Hospital Department of Cardiology, Aarhus, Denmark.
Dotter, M.D., Charles T., “Transluminal Treatment of Arteriosclerotic Obstruction,” University of Oregon's Minthorn Memorial Laboratory for Cardiovascular Research through Radiology, Circulation, vol. XXX, Nov. 1964, pp. 654-670.
Inoue, M.D., Kanji, et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter,” The Journal of Thoracic and Cardiovascular Surgery 87:394-402, 1984.
Pavcnik, M.D., Ph.D., Dusan, et al. “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology 1992; 183:151-154.
Rashkind, M.D., William J., “Historical Aspects of Interventional Cardiology: Past, Present, Future,” Texas Heart Institute Journal, Interventional Cardiology, pp. 363-367.
Rösch, M.D., Josef, “The Birth, Early Years and Future of Interventional Radiology,” J Vasc Interv Radiol 2003; 14:841-853.
Ross, F.R.C.S., D.N., “Aortic Valve Surgery,” Guy's Hospital, London, pp. 192-197, approximately 1968.
Sabbah, Ph.D., Hani N., et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Journal of Cardiac Surgery, vol. 4, No. 4, pp. 302-309, Dec. 1989; ISSN 0886-0440.
Wheatley, M.D., David J., “Valve Prostheses,” Rob & Smith's Operative Surgery, Fourth Edition, pp. 415-424, Butterworths 1986.
Bavaria, Joseph E. M.D. et al.: “Transcatheter Mitral Valve Implantation: The Future Gold Standard for MR?,” Applicant requests the Examiner to consider this reference to be prior art as of Dec. 2010.
Backer, Ole De, MD, et al., “Percutaneous Transcatheter Mitral Valve Replacement—An Overview of Devices in Preclinical and Early Clinical Evaluation,” Contemporary Reviews in Interventional Cardiology, Circ Cardiovasc Interv. 2014;7:400-409, Applicant believes this may have been available as early as Jun. 2014.
Bavaria, Joseph E. M.D.: “CardiAQ Valve Technologies: Transcatheter Mitral Valve Implantation,” Sep. 21, 2009.
Berreklouw, Eric, PhD, et al., “Sutureless Mitral Valve Replacement With Bioprostheses and Nitinol Attachment Rings: Feasibility In Acute Pig Experiments,” The Journal of Thoracic and Cardiovascular Surgery, vol. 142, No. 2, Aug. 2011 in 7 pages, Applicant believes this may have been available online as early as Feb. 7, 2011.
Boudjemline, Younes, et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves,” JACC, vol. 46, No. 2, Jul. 19, 2005:360-5.
CardiAQ Valve Technologies, “Innovations in Heart Valve Therapy,” In3 San Francisco, Jun. 18, 2008, PowerPoint presentation in 19 slides.
Chiam, Paul T.L., et al., “Percutaneous Transcatheter Aortic Valve Implantation: Assessing Results, Judging Outcomes, and Planning Trials,” JACC: Cardiovascular Interventions, The American College of Cardiology Foundation, vol. 1, No. 4, Aug. 2008:341-50.
Condado, Jose Antonio, et al., “Percutaneous Treatment of Heart Valves,” Rev Esp Cardio. 2006;59(12):1225-31, Applicant believes this may have been available as early as Dec. 2006.
Feldman, Ted, MD. “Prospects for Percutaneous Valve Therapies,” Circulation 2007;116:2866-2877. Applicant believes that this may be available as early as Dec. 11, 2007.
Fitzgerald, Peter J. M.D., “Tomorrow's Technology: Percutaneous Mitral Valve Replacement, Chordal Shortening, and Beyond,” Transcatheter Valve Therapies (TVT) Conference. Seattle, WA. Applicant believes this may have been available as early as Jun. 7, 2010.
Fornell, Dave, ““Transcatheter Mitral Valve replacement Devices in Development,”” Diagnostic and Interventional Cardiology, Dec. 30, 2014, p. 3, <http://www.dicardiology.com/article/transcatheter-mitral-valve-replacement-devices-development>.
Grube, E. et al., “Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.” J Am Coll Cardiol. Jul. 3, 2007;50(1):69-76. Epub Jun. 6, 2007.
Karimi, Houshang, et al., “Percutaneous Valve Therapies,” SIS 2007 Yearbook, Chapter 11, pp. 1-11.
Kronemyer, Bob, ““CardiAQ Valve Technologies: Percutaneous Mitral Valve Replacement,”” Start Up—Windhover Review of Emerging Medical Ventures, vol. 14, Issue No. 6, Jun. 2009, pp. 48-49.
Leon, Martin B., et al., “Transcatheter Aortic Valve Replacement in Patients with Critical Aortic Stenosis: Rationale, Device Descriptions, Early Clinical Experiences, and Perspectives,” Semin. Thorac. Cardiovasc. Surg. 18:165-174, 2006 in 10 pages, Applicant believes this may have been available as early as the Summer of 2006.
Lutter, Georg, et al., “Off-Pump Transapical Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 36 (2009) 124-128, Applicant believes this may have been available as early as Apr. 25, 2009.
Ma, Liang, et al., “Double-Crowned Valved Stents For Off-Pump Mitral Valve Replacement,” European Journal of Cardio-thoracic Surgery 28 (2005) 194-199, Applicant believes this may have been available as early as Aug. 2005.
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: A Short-term Experience in Swine Model,” Applicant believes this may have been presented on May of 2011 at TVT.
Mack, Michael, M.D., “Antegrade Transcatheter Mitral valve Implantation: On-Going Experience in Swine Model,” Applicant believes this may have been presented on Nov. 2011 at TCT.
Ostrovsky, Gene, “Transcatheter Mitral Valve Implantation Technology from CardiAQ,” medGadget, Jan. 15, 2010, available at: http://www.medgadget.com/2010/01/transcatheter_mitral_valve_implantation_technology_from_cardiaq.html.
Preston-Maher, Georgia L., et al., “A Technical Review of Minimally Invasive Mitral Valve Replacements,” Cardiovascular Engineering and Technology, vol. 6, No. 2, Jun. 2015, pp. 174-184. Applicant believes this may have been available as early as Nov. 25, 2014.
Quadri, Arshad M.D., “Transcatheter Mitral Valve Implantation (TMVI) (An Acute In Vivo Study),” Applicant believes this may have been presented on Sep. 22, 2010 at TCT.
Ratz, J. Brent, “LSI EMT Spotlight,” May 15, 2009.
Ratz, J. Brent et al., “Any experiences making an expandable stent frame?” Arch-Pub.com, Architecture Forums: Modeling, Multiple forum postings from Feb. 3, 2009 to Feb. 4, 2009, http://www.arch-pub.com.
Ratz, J. Brent, “In3 Company Overview,” Jun. 24, 2009.
Ruiz, Carlos E., “Overview of Novel Transcatheter Valve Technologies,” Applicant believes this may have been presented on May 27, 2010 at EuroPCR.
Spillner, J. et al., “New Sutureless ‘Atrial-Mitral-Valve Prosthesis’ For Minimally Invasive Mitral Valve Therapy,” Textile Research Journal, 2010, in 7 pages, Applicant believes this may have been available as early as Aug. 9, 2010.
Sondergaard, Lars, et al., “Transcatheter Mitral Valve Implantation: CardiAQ™,” Applicant believes this may have been presented at TCT 2013.
Sondergaard, Lars, et al., “Transcatheter Mitral Valve Implantation: CardiAQ™,” Applicant believes this may have been presented at EuroPCR 2013.
Sondergaard, Lars, “CardiAQ TMVR FIH—Generation 2,” Applicants believe this may have been presented in 2014 at the TVT symposium.
Treede et al.: “Transapical transcatheter aortic valve implantation using the JenaValve™ system: acute and 30-day results of the multicentre CE-mark study.” http://ejcts.oxfordjournals.org/content/41/6/e131.long. Apr. 16, 2012.
Taramasso et al.: “New devices for TAVI: technologies and initial clinical experiences” http://www.nature.com/nrcardio/journal/v11/n3/full/nrcardio.2013.221.html?message-global=remove#access. Jan. 21, 2014.
Webb, John G., et al., “Transcatheter Aortic Valve Implantation: The Evolution Of Prostheses, Delivery Systems And Approaches,” Archives of Cardiovascular Disease (2012) 105, 153-159. Applicant believes this may have been available as early as Mar. 16, 2012.
Wayback Machine, Cleveland Clinic Lerner Research Institute, Transcatheter Mitral Stent/Valve Prosthetic, https://web.archive.org/web/20130831094624/http://mds.clevelandclinic.org/Portfolio.aspx?n=331, indicated as archived on Aug. 31, 2013.
“Company Overview,” at TVT on Jun. 25, 2009.
BioSpace, “CardiAQ Valve Technologies (CVT) Reports First-In-Human Percutaneous Transfemoral, Transseptal Implantation With Its Second Generation Transcatheter Bioprosthetic Mitral Heart Valve,” Jun. 23, 2015, p. 1, http://www.biospace.com/News/cardiaq-valve-technologies-cvt-reports-first- in/382370.
BioSpace, “CardiAQ Valve Technologies (CVT) Reports Cardiovascular Medicine Milestone: First-In-Humannonsurgical Percutaneous Implantation of a Bioprosthetic Mitral Heart Valve,” Jun. 14, 2012, p. 1, http://www.biospace.com/News/cardiaq-valve-technologies-cvt-reports/263900.
Neovasc corporate presentation, Oct. 2009, available at http://www.neovasc.com/investors/documents/Neovasc-Corporate-Presentation-October-2009.pdf.
AGA Medical Corporation. www.amplatzer.comproducts. “The Muscular VSD Occluder” and “The Septal Occluder” device description. Accessed Apr. 3, 2002.
Anand et al.; Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction; Circulation ; 96(11); pp. 3974-3984; Dec. 1997.
Artrip et al.; Left ventricular vol. reduction surgery for heart failure: A physiologic perspective; J Thorac Cardiovasc Surg; vol. 122; No. 4; pp. 775-782; Oct. 2001.
Boersma et al.; Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour; Lancet: vol. 348(9030); pp. 771-775; Sep. 21, 1996.
Bozdag-Turan et al.; Left ventricular partitioning device in a patient with chronic heart failure: Short-term clinical follow-up; Int J Cardiol; 163(1); pp. e1-e3; (Epub) Jul. 2012.
Dang et al.; Akinetic myocardial infarcts must contain contracting myocytes: finite-element model study; Am J Physiol Heart Circ Physiol ; 288; pp. H1844-H1850; Apr. 2005.
Dang et al.; Effect of ventricular size and patch stiffness in surgical anterior ventricular restoration: a finite element model study; Ann Thorac Surg; 79; pp. 185-193; Jan. 2005.
Di Mattia et al. Surgical treatment of left ventricular post-infarction aneurysm with endoventriculoplasty: late clinical and functioal results. European Journal of Cardio-thoracic Surgery. 15(4):413-418; Apr. 1999.
Dor et al. Ventricular remodeling in coronary artery disease. Current Opinion in Cardiology. 12(6):533-537; Nov. 1997.
Dor V. The treatment of refractory ischemic ventricular tachycardia by endoventricular patch plasty reconstruction of the left ventricle. Seminars in Thoracic and Cardiovascular Surgery. 9(2): 146-155; Apr. 1997.
Dor. Surgery for left ventricular aneurysm. Current Opinion in Cardiology. vol. 5; No. 6; pp. 773-780; Dec. 1990.
Gore Medical. www.goremedical.com. “Helex Septal Occluder” product description. Accessed Apr. 3, 2002.
Grossman et al.; Wall stress and patterns of hypertrophy in the human left ventricle; J Clin Invest; 56; pp. 56-64; Jul. 1975.
Guccione et al.; Finite element stress analysis of left ventricular mechanics in the beating dog heart; J Biomech; 28; pp. 1167-1177; Oct. 1995.
Guccione et al.; Mechanics of active contraction in cardiac muscle: Part II—Cylindrical models of the systolic left ventricle; J Biomech Eng; 115; pp. 82-90; Feb. 1993.
Gutberlet et al.; Myocardial viability assessment in patients with highly impaired left ventricular function: comparison of delayed enhancement dobutamine stress MRI end-diastolic wall thickness and TI201-SPECT with functional recovery after revascularization; Eur Radiol; 15; pp. 872-880; May 2005.
Huisman et al.; Measurement of left ventricular wall stress; Cardiovascular Research; 14; pp. 142-153; Mar. 1980.
James et al.; Blood Volume and Brain Natriuretic Peptide in Congestive Heart Failure: A Pilot Study; American Heart Journal; vol. 150; issue 5 pp. 984.e1-984.e6 (abstract); Dec. 6, 2005.
Januzzi James L.; Natriuretic peptide testing: A window into the diagnosis and prognosis of heart failure; Cleveland Clinic Journal of Medicine; vol. 73; No. 2; pp. 149-152 and 155-157; Feb. 2006.
Jones et al.; Coronary Bypass Surgery with or without Surgical Ventricular Reconstruction; N Engl J Med; 360; pp. 1705-1717; Apr. 2009.
Kawata et al. Systolic and Diastolic Function after Patch Reconstruction of Left Ventricular Aneurysms. Ann. Thorac. Surg. 5(2)9:403-407; Feb. 1995.
Lee et al.; A novel method for quantifying in-vivo regional left ventricular myocardial contractility in the border zone of a myocardial infarction (author manuscript 11 pgs.); J Biomech Eng; 133; 094506; Sep. 2011.
Mazzaferri et al.; Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: Results of the Percutaneous Ventricular Restoration in Chronic Heart Failure Patients Trial; Am Heart J; 163; pp. 812-820; May 2012.
Nikolic et al.; Percutaneous implantation of an intraventricular device for the treatment of heart failure: experimental results and proof of concept; J Card Fail; 15(9); pp. 790-797; Nov. 2009.
Priola et al.; Functional characteristics of the left ventricular inflow and outflow tracts; Circ Res; 17; pp. 123-129; Aug. 1965.
Sagic et al.; Percutaneous implantation of the left ventricular partitioning device for chronic heart failure: a pilot study with 1-year follow-up. Eur J Heart Fail; 12; pp. 600-606; Apr. 2010.
Sun et al.; A computationally efficient formal optimization of regional myocardial contractility in a sheep with left ventricular aneurysm (author manuscript 21 pgs.); J Biomech Eng; 131; 111001; Nov. 2009.
U.S. Food & Drug Administration; AneuRx Stent Graft System-Instructions for use; (pre-market approval); Sep. 29, 1999; downloaded Apr. 25, 2013 (http:www.accessdata.fda.govcdrh_docspdfP990020c.pdf).
Walker et al; Magnetic resonance imaging-based finite element stress analysis after linear repair of left ventricular aneurysm (author manuscript 17 pgs.); J Thorac Cardiovasc Surg; 135; pp. 1094-1102 e1-2; May 2008.
Walker et al; MRI-based finite element analysis of left ventricular aneurysm; Am J Physiol Heart Circ Physiol; 289; pp. H692-H700; Aug. 2005.
Walmsley; Anatomy of left ventricular outflow tract; British Heart Journal; 41; pp. 263-267; Mar. 1979.
Wenk et al.; First evidence of depressed contractility in the border zone of a human myocardial infarction; Ann Thorac Surg; 93; pp. 1188-1193; Apr. 2012.
Wenk et al.; Regional left ventricular myocardial contractility and stress in a finite element model of posterobasal myocardial infarction (author manuscript pgs.); J Biomech Eng; 133(4); 044501; Apr. 2011.
Related Publications (1)
Number Date Country
20230285149 A1 Sep 2023 US
Continuations (2)
Number Date Country
Parent 16997634 Aug 2020 US
Child 18199420 US
Parent 15506562 US
Child 16997634 US